(Circulation. 1997;96:4065-4082.)
© 1997 American Heart Association, Inc.
Articles |
From the Division of Cardiology, Department of Internal Medicine, University of Missouri Health Sciences Center, Columbia.
Correspondence to Karl T. Weber, MD, Division of Cardiology, MA432 Medical Sciences Building, University of Missouri Health Sciences Center, Columbia, MO 65212.
Key Words: angiotensin collagen diastole heart failure remodeling
| Introduction |
|---|
|
|
|---|
ACE inhibition has proved effective in reducing mortal and morbid events, improving symptomatic status, and attenuating the progressive nature of cardiac failure in symptomatic patients with ventricular diastolic and/or systolic dysfunction in whom activation of the circulating RAAS is present.1,13,14 ACE inhibitormediated reductions in circulating Ang II and aldosterone no doubt contribute to this salutary response. This would include an attenuation of well-recognized endocrine properties of these hormones, such as altered sodium homeostasis and vascular tonicity, and their adverse influence on matrix structure of atria and ventricles.1520 Collectively, these adverse responses to RAAS effector hormones contribute to the progressive nature of chronic cardiac failure, which includes recurring bouts of symptomatic failure1,2,21 and reentrant arrhythmias originating in either atria or ventricles.22,23
ACEIs have also proved effective in asymptomatic patients
with equivalent levels of ventricular systolic
dysfunction but in whom chronic RAAS activation is not
present.2,24,25 Attention has therefore
focused on the importance of Ang II generated de novo within the
infarcted heart.26 ACE, a membrane-bound
ectoenzyme found on various cells, is central to Ang II generation
within an organ.27 Because ACE mRNA expression
and activity are each increased in tissue homogenates taken
from either the infarcted failing ventricle or the hypertrophied,
hypertensive ventricle,2832 it has been
proposed that these responses are a consequence of cardiac myocyte
hypertrophy and/or increased systolic wall
stress.31,32 Increased ACE activity, however, is
most specifically localized to sites of fibrosis, such as
ventricular aneurysm in the infarcted
heart,29 a finding reinforced by
autoradiographic localization of high-density ACE binding
at the site of MI.33 Marked ACE binding is also
seen at sites of repair remote from the infarct (eg, noninfarcted right
ventricle) and sites independent of infarction (eg, fibrosed visceral
pericardium),33 where ACE activity (Ang I
substrate conversion) is present.30,34 Hence,
increased expression of ACE transcript and activity do not appear to be
related to hemodynamic factors or to cardiac myocyte
hypertrophy. Cells expressing ACE at sites of repair
include a phenotypically transformed fibroblast-like cell, the myoFb,
because it expresses
-SMA and is
contractile.35,36
Locally produced Ang II has autocrine and paracrine properties that influence the behavior of constitutive cell populations of the myocardium via Ang II receptor binding. Various paradigms have been suggested, including Ang IImediated cardiac myocyte hypertrophy37 and apoptosis,38,39 regulation of microvascular blood flow at sites of injury,40 and the process of tissue repair itself.41
This report addresses various lines of evidence that implicate Ang II, generated de novo at sites of high collagen turnover, in regulating connective tissue formation. This applies to normal (eg, heart valve leaflets) and pathological sites of tissue repair. On the basis of these collective findings, it is suggested that Ang II, produced de novo at sites of injury in the heart and pericardium, is integral to their repair. Let's set the stage for this Bench to Bedside review with a fictional vignette.
| Clinical Vignette: Bee Stings and Other Things |
|---|
|
|
|---|
Mindy sat at her desk to ponder Joseph's fibrocontractive disorder, her mind struggling to understand its pathophysiological basis. She began drumming the eraser end of her pencil on the desk to an imaginary rhythm. Like a Gene Krupa drum solo from the swing era of jazz, her rendition built in intensity and pace. "Strange," she thought, "a drumhead's stretched membrane of cowhide does not contract. Why would Joseph's palmar fascia?" For that matter, why would scarred rheumatic mitral leaflets retract and become incompetent? There were no contractile proteins in fibrous tissue to mediate such responses. Or were there? She quickly turned to her personal computer for a search of the medical literature in hopes of unraveling the puzzle. As an internistintegrator of basic and clinical sciencesshe reminded herself that tissue, defined as a substance of an organ, consists of intercellular material, in this case fibrillar collagen, and cells. "That's it," she exclaimed, "it must be the cells!" Bursting with ideas, her mind racing, she wondered whether such circumstances could also explain Mrs Carver's problem.
Mindy had seen Ruth Carver in the ICU earlier in the day. This 67-year-old woman had had an uneventful anterior MI 6 months earlier, without clinical evidence of ventricular dysfunction or arrhythmia. After hospital discharge, she noted the gradual appearance of dyspnea with moderate levels of exertion, particularly evident over the past several months. Last evening, paramedics brought Ruth to the ER because of severe breathlessness. There, Mindy found her tachypneic and orthopneic: blood pressure 180/100 and an irregular heart rate of 140 bpm, with a pulse deficit of 50 bpm. She denied chest pain. Neck veins were not distended, apical impulse not displaced; no S3 gallop or murmur; bibasilar crackles without pleural effusion, hepatomegaly, or pitting ankle edema. The ECG showed atrial fibrillation without acute MI or ischemia. Serum creatine kinase MB fraction likewise did not support MI. Mindy's diagnosis: acute pulmonary edema. She chose electrical cardioversion to restore sinus rhythm and intravenous furosemide to induce a diuresis and clear pulmonary congestion. Thereafter, Mrs Carver's blood pressure returned to its usual normotensive value and she was breathing more comfortably; she was hospitalized for further observation.
Mindy was gratified this morning when she noted Ruth's continued recovery. But she was curious. The appearance of atrial fibrillation, with rapid ventricular rate and lost atrial contraction, was inextricably linked to her pulmonary edema. Other patients Mindy followed, without structural heart disease, had tolerated similar episodes of atrial fibrillation without such sequelae. Why had atrial fibrillation precipitated pulmonary edema in Ruth? DD with acute pulmonary venous hypertension seemed most likely. Mindy obtained an echocardiogram from the health center's outreach program later in the day: ejection fraction, 45%; DD as evidenced by an abnormal E/A wave ratio; and absent mitral valve incompetence or ventricular aneurysm. With her clinical impression confirmed, she wondered: What leads to DD after infarction? Mindy pondered whether the hands of the McKenzie family provided clues.
Mindy prescribed an ACEI and in subsequent weeks was delighted when Ruth no longer experienced dyspnea on exertion. Her patient's annoying cough would prompt a switch to an AT1 receptor antagonist. A repeat echocardiogram, months later, would demonstrate improved DD and an ejection fraction of 52%.
| Ventricular Dysfunction and the Clinical Spectrum of Heart Failure |
|---|
|
|
|---|
LVD per se does not account for a decompensated clinical state of
symptomatic cardiac failure.1,2 This
has been clearly underscored by the Studies of Left
Ventricular Dysfunction (SOLVD) trial, in which an ejection
fraction
35% as entrance criterion was satisfied in both
symptomatic patients with decompensated failure (treatment
arm) and asymptomatic patients with compensated failure
(prevention arm).1,2 Decompensated failure is
manifested by signs and symptoms of extravascular volume expansion (eg,
pleural effusion, pitting edema). It occurs when renal perfusion is
significantly impaired and accompanied by marked proximal and distal
tubular sodium resorption. This sodium-avid state is mediated via a
chronic activation of the circulating RAAS.5557
Accompanying elevations in circulating Ang II and
aldosterone are inappropriate as contrasts to states of
sodium deprivation or intravascular volume depletion.
Compensated failure, in which patients are asymptomatic,
exists when the circulating RAAS has not been activated and as
a result renal sodium excretion remains normal.
Ventricular diastolic and systolic
dysfunction is based on an adverse structural remodeling of the
myocardium (see Fig 1
). This
includes the population of cardiac myocytes, in which, over time,
hypertrophy, necrosis, and apoptosis alter myocyte
mass, and a progressive accumulation of fibrous tissue. Fibrosis
appears in morphologically distinct forms. This includes a reactive
form, expressed as a perivascular/interstitial fibrosis,
which appears in the absence of myocyte necrosis, and a reparative
fibrosis or microscopic scars that replace necrotic
myocytes.15 Initially, fibrous tissue will
adversely influence tissue stiffness and diastolic
mechanics.5,6,9,5862 This includes recruiting
the length-dependent property of cardiac muscle (Frank-Starling
mechanism) during volume loading,8,63,64 such as
occurs with increased venous return attendant on incremental isotonic
exercise. A continued accumulation of matrix further impairs
diastolic stiffness and now compromises systolic
mechanics, including tissue
contractility.6,65 Ultimately,
renal perfusion falters. Decompensated failure is associated with
increased mRNA expression of matrix proteins (eg, types I and III
collagens) and accumulation of corresponding proteins expressed as
cardiac fibrosis.6668
|
| Cardiac Remodeling and the Infarcted Heart |
|---|
|
|
|---|
Overview of Tissue Repair
Healing is a property common to all vascularized tissues. A
reparative process is initiated after cardiac myocyte necrosis. This
initially depends on inflammatory cells, such as monocytes and
macrophages, that invade the site of injury.
Macrophages are activated and thereafter generate
peptides integral to repair. Fibroblasts are subsequently attracted to
the site of injury, where they convert to myoFbs. Through a complex
series of molecular events that includes expression of immediate early
response genes (eg, c-fos, c-jun, and
egr-1) and activation of multiple second messenger systems,
which act synergistically to induce mitosis, these cells proliferate
and lay down fibrillar collagen that replaces lost
myocytes.6972 Cells involved in repair are
bathed by tissue fluid whose composition regulates their
phenotype and behavior. A diverse array of soluble regulatory
signals, whose biological properties are expressed via receptor-ligand
binding, gain access to tissue fluid of the interstitial
space from necrotic myocytes, leukocytes, macrophages, and
myoFbs. Monitoring lymphatic7375 or venous
drainage76,77 of the injured heart provides
insights to the nature of these signals and their broad-ranging
functions that regulate cell migration and differentiation, cell-cell
interactions, and gene expression.78
Fibrous tissue formation is essential to preserving structural integrity of the infarcted myocardium at the site of myocyte loss. Provided that the degree of parenchymal damage is minor, regulatory signals are confined to the site of necrosis. This resembles the local release of histamine and the subsequent wheal-and-flare response that accompanies a single bee sting. Multiple bee stings evoke a large histamine response widely dispersed within tissue fluid, which then promotes diffuse organ swelling. Such is the case with a large transmural MI, in which signals originating at the site of injury are widely dispersed within the common interstitial space of both ventricles to elicit a fibrogenic response in the noninfarcted portion of the injured ventricle and the noninfarcted ventricle.33,64,79,80 Signals involved in repair after MI, however, are confined to the heart; systemic organs are not involved. When fibrogenic signals gain access to the circulation (see below) and are not neutralized, systemic organs will be involved in an unwanted accumulation of stromaa wound-healing response gone awry.
Collagen Turnover At and Remote From Infarction
Collagen turnover has been studied at the site of infarction and
at remote sites after ligation of the rat left coronary artery.
At the infarct site, collagen degradation, particularly its neutral
salt and acid-soluble fractions,81 exceeds
synthesis during the very early phase of repair. MMPs reside in the
myocardium in latent form. When activated, MMP-1
(or interstitial collagenase) degrades
fibrillar collagen into 1/4-length and 3/4-length
fragments; gelatinases (MMP-2 and MMP-9) degrade these smaller
fragments. An increase in collagenase activity appears at
the infarct site on day 2, peaks by day 7, and declines thereafter,
together with increased gelatinase activity.82 An
increase in collagenase (MMP-1) mRNA expression appears
only at day 7 in the infarcted ventricle, replacing the consumed latent
pool. TIMPs neutralize collagenolytic activity. Transcription of TIMP
mRNA at the infarct site peaks on day 2 and declines slowly over the
course of 14 days. Events related to collagen degradation are not seen
remote from the MI. Fibroblast-like cells, not inflammatory or
endothelial cells, are responsible for the
transcription of MMP-1 and TIMP mRNAs.82
A fibrogenic component of healing, including an initial expression of
fibronectin mRNA,83 follows early collagen
degradation. By Northern blot and in situ hybridization
analyses, type III procollagen mRNA at the infarct site is
increased by day 2 post-MI, reaching a peak by day 21 and declining
thereafter.84 Type I procollagen mRNA increases
at day 4 and remains elevated at week 4 (see Fig 2A
) and even until day 90 at the site of
infarction,84 suggesting that collagen synthesis
is an ongoing process in keeping with the persistence of myoFbs at this
site.85,86 To a lesser extent than seen at the
site of injury, but still evident, is the rise in procollagen mRNA
remote from the infarct.84,87 Procollagen I and
III mRNAs are increased in the right ventricle and
interventricular septum on days 4 and 7,
respectively.84 In the septum, closest to the
infarct, type I procollagen mRNA remains elevated until day 28 (see Fig 2A
) but in the right ventricle only until day 7. Expression of type I
collagen mRNA is also increased in the fibrosed visceral pericardium at
week 4 post-MI (see Fig 2A
). These responses, involving myoFbs at the
infarct and remote sites (see below),84,86 are
associated with increased expression of TGF-ß1
mRNA.87
|
By picrosirius red staining, collagen fibers are morphologically
evident at the infarct site by day 7, and an organized assembly of
fibers in the form of scar tissue becomes evident by day 14 and
continues to accumulate for many weeks (see Fig 2B
).33,88 Hydroxyproline concentration at the
site of scarring increases progressively from week 1 to week 6, as does
collagen crosslinking.8991 A thinning of
infarct scar is evident by week 8. Remote from the infarct, including
viable left ventricle, interventricular septum, and right
ventricle, fibrillar collagen appears by day 14, continues to
accumulate for weeks (see Fig 2B
), and is associated with increased
pepsin-insoluble collagen.4,62,64,79,80,91
MyoFbs and Repair
MyoFbs are central to fibrogenesis at sites of repair. Fibroblasts
have an extensive clonal heterogeneity, and these
phenotypically transformed fibroblast-like cells have considerable
diversity.35,92 This includes their synthesis of
structural proteins and expression of receptors for Ang II,
TGF-ß1, and endothelins, which permit their
response to these regulatory molecules. In addition, myoFbs express
-SMA and are contractile, and, relevant to this report, they govern
fibrogenesis in the heart,86,93,94 pericardium,
and systemic organs secondary to diverse forms of
injury.35 These
-SMApositive cells (see Fig 3A
) appear at sites of injury within days
of cardiac myocyte necrosis33,9395 and are
responsible for increased expression of genes encoding for fibrillar
type I/III procollagens and their
synthesis.33,96,97 MyoFbs arise from
interstitial fibroblasts and/or pericytes, not vascular
smooth muscle cells or cardiac myocytes.35,36
MyoFb contraction governs matrix remodeling, including scar
thinning.98 The contractile behavior of fibrous
tissue is related to myoFbs having
-SMA and their cell-cell
(desmosome and gap junction types) and cell-matrix (fibronexus, a
transmembrane association between fibronectin fibers and actin
microfilaments) connections. Their influence on DD of the infarcted
ventricle and abnormal tissue stiffness at remote sites will be
addressed later in this report.
|
Signals that determine the appearance of the myoFb phenotype
are not entirely certain. TGF-ß1 is
contributory. Subcutaneous administration of
TGF-ß1 leads to the appearance of myoFbs within
granulation tissue that forms, which is not the case for
platelet-derived growth factor or tumor necrosis
factor-
.99 Cultured adult skin fibroblasts
undergo a phenotype switch and express
-SMA when incubated
with TGF-ß1.99 The
appearance of TGF-ß1 at sites of injury is most
likely related to necrotic myocytes,100,101
activated macrophages,102 and
myoFbs themselves.103
A fibrillar fibrin-fibronectin scaffolding forms soon after tissue injury and is the precursor to granulation tissue formation and the attachment of myoFbs via a fibronexus.104 MyoFbs subsequently elaborate type III and then type I collagens, the major fibrillar collagens that constitute fibrous tissue.105107 At pathological sites of tissue repair in the heart, including the site of MI, in situ hybridization has shown that myoFbs express types I and III collagen transcripts.33,84 MyoFbs elaborate and metabolize various substances that regulate their turnover of collagen and govern fibrous tissue contraction in an autocrine manner (see below).
Via apoptosis, or programmed cell death, myoFbs (or a subpopulation of myoFbs) are generally reduced in number at sites of repair involving the heart33,93; with skin injury, they completely disappear.108,109 Apoptosis does not elicit an inflammatory cell response and subsequent fibrosis.110 In the infarcted heart, myoFbs persist at the MI site long after infarct healing has been completed.85 In the kidney injured by experimental glomerulonephritis, persistence of myoFbs is associated with a progressive interstitial fibrosis.103 Irrespective of the location or nature of the inciting stimulus to connective tissue formation in the heart, myoFbs are the dominant cell involved in matrix formation.86
| Angiotensin II and Tissue Repair in the Heart and Other Organs |
|---|
|
|
|---|
Localization of ACE and Ang II Receptors and ACE Activity
The role of Ang II in the fibrogenic phase of tissue repair has
recently come under investigation. Requisite factors for the
involvement of this peptide in tissue repair include its local
production at functionally relevant concentrations and the
presence of stereospecific Ang II receptors on cells that regulate
collagen turnover.
The localization and density of ACE binding in the normal and injured heart have been examined with quantitative in vitro autoradiography and an iodinated derivative of lisinopril (125I-351A).33,86,121125 In the normal heart, low-density ACE binding is found throughout ventricular myocardium and atria, whereas high-density binding is present at sites of high collagen turnover, including heart valve leaflets and the adventitia of intramyocardial coronary arteries.125128 High-density ACE binding is likewise found in subcutaneous skin, with its metabolically active fibroblasts, but not skeletal muscle tendon, in which fibrocytes are quiescent.125 Immunolabeling with a monoclonal ACE antibody129 identified cells expressing this ectoenzyme. They include endothelial cells on the surface of each valve leaflet; myoFb-like cells, also called valvular interstitial cells, residing within leaflet matrix, where they are responsible for collagen turnover; and pericytes in the adventitia of intramural vessels. Autoradiography and immunolabeling have further demonstrated ACE binding in cultured intact myoFb-like cells and in their cell membranes.130 RT-PCR with amplification of total RNA has demonstrated the presence of ACE mRNA in these cells. Substrate utilization of membrane-bound ACE in these cells includes Ang I and, in its dual capacity as a kininase II, other chemical mediators of inflammation, such as BK and substance P. Thus, myoFb-like cells of valve leaflets have the potential to regulate local concentrations of Ang II and other mediators of tissue repair, such as TGF-ß1, in valve leaflets. The importance of the TGF-ß family of peptides in fetal heart development, including endocardial cushion formation and heart valve induction, has recently been reported.131,132 A role for Ang II generated by these cells in contributing to this process should be considered.
High-affinity receptors are integral to the biological activity of such ACE-related peptides. The presence of Ang II receptors in heart valves was demonstrated by autoradiography using 125I[Sar,1 Ile8]-Ang II binding.125 Competitive binding using either an AT1 or AT2 receptor antagonist, losartan or PD123177, respectively, provided identification of receptor subtype. Low-density AT1 receptor binding is present throughout the myocardium, whereas high-density binding is present in heart valve leaflets.125 Western immunoblot, as well as binding assay, confirmed these findings in membranes.130 Heart valves and myoFbs membranes likewise contain BK receptors, as seen by 125I[Tyr8]-BK autoradiographic binding125 and binding assay.130
Cellular responses to Ang II receptorligand binding has been
examined in serum-deprived, cultured myoFb-like cells obtained from
adult rat heart valve leaflets. By in situ hybridization, these cells
express the transcript for type I collagen, and incubation of cultured
cells with Ang II in pathophysiological
concentrations enhances type I collagen synthesis via
AT1 receptor
binding.130,133,134
Immunohistochemistry130,135 and electron
microscopy136,137 have shown that these cells and
pericytes each contain
-SMA microfilaments. These microfilaments
confer contractile behavior to these cells, and various substances,
including Ang II, promote their
contraction.136,137
Collectively, these findings implicate a biological role for ACE in the local regulation of Ang II and BK at normal tissue sites where collagen turnover is high. These findings led to additional autoradiographic and morphological studies in the rat in several different models of experimental tissue injury involving the heart, related structures, or systemic organs.
High-density autoradiographic ACE binding was found
at the site of MI at week 1 and increased progressively over the course
of 8 weeks (see Fig 2C
) in parallel with morphological evidence of
fibrillar collagen accumulation found in serial heart
sections.33 ACE activity, as measured by
substrate conversion, is increased in aneurysmal tissue of the
infarcted LV compared with atrial tissue.29 In
addition, a significant correlation was found between ACE activity and
the extent of infarction,29 as is also the case
for ACE mRNA expression and activity at sites remote from the
MI.30 In the rat model of MI, the circulating
RAAS is not activated.30,138141
By use of either monoclonal (see Fig 3B
) or polyclonal ACE
antibodies, ACE-labeled cells at sites of healing were
identified.33,84,142 After cardiac myocyte
necrosis, they include macrophages,
-SMApositive myoFbs,
and endothelial cells of the neovasculature.
High-density ACE binding is also found at sites of fibrosis remote from
the MI (see Fig 2C
). This includes endocardial fibrosis of the
interventricular septum, interstitial fibrosis
of the right ventricle, the fibrosed pericardium that follows
pericardiotomy (with or without infarction), and the foreign-body
fibrosis that surrounds the silk ligature placed around the left
coronary artery as part of a sham operation. The anatomic
coincidence between high-density ACE binding and fibrosis has been
observed in other injured organs of the rat, including the infarcted
kidney and incised skin sutured with silk
ligature.123 Immunolabeling demonstrated myoFbs
containing
-SMA as cells expressing ACE at each of these
noninfarcted related sites (see Fig 3C
and 3D
). High-density ACE
binding is also observed at sites of isoproterenol-induced myocyte
necrosis.143,144 At all of these sites of repair,
in situ hybridization and immunolabeling demonstrated myoFbs as
expressing genes encoding for type I and III
collagens.33,84
In vitro quantitative autoradiography was likewise used
to address Ang II receptor binding in the infarcted rat heart, with
receptor subtype determined by displacement with an
AT1 (losartan) or
AT2 (PD 123177) receptor
antagonist.135,145147 Marked
AT1 receptor binding density is present at
the site of MI and endocardial and pericardial fibrosis (see Fig 2D
),
whereas AT2 receptor binding is low at these
sites. Cells expressing AT1 receptors at sites of
injury are myoFbs (see Fig 3E
and 3F
).148 These
autoradiographic findings are consistent with the
increase in gene transcription and protein expression of the
AT1 receptor found in homogenized
tissue taken from the site of MI and remote sites by RT-PCR and binding
assays.149,150 AT1Ra
abrogates this response, which is not the case for an
AT2Ra. Increased expression of Ang II receptors
likewise appears in other organs at sites of injury, such as
skin.151153
In an isolated, crystalloid-perfused organ preparation, the conversion of Ang I to Ang II by epicardium of normal rat hearts was contrasted to hearts with fibrosis of the visceral pericardium 4 weeks after pericardiotomy (without MI).34 ACE activity of the fibrosed pericardium was severalfold higher than in the normal heart, and Ang II generation was completely abrogated by ACEI. This finding also suggests that in rats, an alternative Ang IIgenerating pathway (eg, a chymase) is not operative in fibrous tissue. High-density ACE binding is likewise present in the perivascular fibrosis and microscopic scars that appear in the right and left atria and ventricles with the chronic administration of Ang II or aldosterone (in uninephrectomized rats on a high-sodium diet).19,121 These latter models demonstrate that ACE binding density within fibrous tissue is independent of circulating Ang II or aldosterone, in contrast to endothelial ACE of the pulmonary artery, which is subject to negative feedback regulation by circulating Ang II.154
The anatomic coincidence between the expression of ACE and
AT1 receptors with normal and pathological
expressions of collagen formation is evident. High-density ACE and Ang
II receptor binding, in fact, are markers of active collagen turnover.
-SMAcontaining, fibroblast-like cells, found within valve
leaflets, adventitia, and various sites of fibrous tissue formation,
express genes encoding for ACE, AT1 receptors,
and fibrillar collagens. MyoFbs could therefore be considered a
"metabolic entity" regulating their own collagen
turnover.41
ACE binding density is related primarily to the presence of myoFbs. The disappearance of ACE-positive cells or a reduction in their absolute number would reduce ACE binding density at sites of fibrosis. Such is the case with old sarcoid granulomas.155 Both ACE and Ang II receptor binding densities in the infarcted rat heart remain high for many months after MI,33,145 as does ACE activity.30 Each is in keeping with the persistence of myoFbs at the infarct site.85 These findings could contribute to the identification and localization of active (cellular) fibrogenesis in an organ by noninvasive technologies similar to autoradiography. Other techniques that characterize the composition of tissue, such as high-frequency ultrasound156 that detects fibrillar collagen, are not dependent on the presence of ACE and myoFbs. Together, such techniques could identify the relative age of fibrosis and its cellularity, which could guide interventional strategies.
De Novo Angiotensin II Generation
Granulation tissue and its diverse cell populations in particular
generate peptides integral to tissue repair via receptor-ligand
binding. ACE, for example, regulates local concentrations of Ang II and
BK. At the infarct site, the concentration of Ang II is increased
severalfold above that found in viable
myocardium.139 De novo Ang peptide
generation requires expression of several requisite components:
angiotensinogen, the precursor to all Ang peptides; a
protease that cleaves away amino acids from angiotensinogen
to form Ang I; and ACE, which hydrolyzes the decapeptide Ang I to Ang
II, an octapeptide. An independent pathway of Ang II generation
involving a chymase has been suggested; however, increased expression
of its transcript is infrequently found in the failing human
heart.28
In situ hybridization localized angiotensinogen mRNA expression in the adult rat heart and aorta to fibroblasts and brown adipocytes.157,158 RT-PCR amplification identified angiotensinogen mRNA expression in the adult human heart.159 This transcript and that of renin are localized within both neonatal fibroblasts and cardiac myocytes,160 with Ang I and Ang II peptides detected in culture media.161 The presence of renin mRNA in normal adult heart tissue is controversial, however, and therefore, the source of cardiac renin has come into question.162 Danser et al163165 showed that this protease is taken up from the circulation and is of renal origin. Renin rapidly disappears from the heart after nephrectomy.166 The presence of other aspartyl (eg, cathepsin D) or serine (eg, cathepsin G) proteases eliminates any absolute dependence on renin as a rate-dependent protease.40,167 This is the case for cultured myoFbs that express cathepsin D and elaborate Ang I133,168; renin mRNA and renin activity have not been detected in either cell population. Several recent studies, however, have reported renin mRNA expression in the adult rat heart.169171 The validity of a renin-angiotensin system in local Ang II generation awaits further investigation.
Pharmacological Modulation of Repair
Evidence supporting a contribution of locally produced Ang II in
regulating myoFb collagen synthesis is obtained with pharmacological
probes that interfere with local Ang II generation (ie, ACEI) or
occupancy of its AT1 receptor. Collagen formation
in the heart and vasculature is rapid soon after birth. In 4-week-old
rats treated with enalapril for 6 weeks, collagen formation in both the
right and left ventricles, aorta, and superior mesenteric artery was
retarded compared with untreated normal 10-week-old
controls.172 In 4-week-old spontaneously
hypertensive rats, a small dose of quinapril, which did not prevent the
ultimate appearance of hypertension, prevented the expected rise in
aortic collagen volume fraction compared with untreated 30-week-old
spontaneously hypertensive rats.173 Each of these
studies implicates local Ang II in regulating normal collagen formation
in the heart and vasculature.
Captopril and enalapril begun at or close to the onset of MI have each reduced infarct size, infarct expansion and thinning, and hydroxyproline concentration at the infarct site in dogs with coronary artery occlusion.174176 The potential contribution of reduced bradykinin degradation to tissue repair that would accompany ACEI is uncertain at present. Several studies suggest that BK is released after MI76,77,177 and that a BK2 receptor antagonist (Hoe140) attenuates collagen accumulation at the MI site.178
Losartan begun on day 1 after coronary artery ligation in a dose that reduced AT1 receptor binding by 50% reduces infarct scar area.179 Moreover, the expected rise in tissue Ang II concentration found at the infarct site 3 weeks after coronary artery ligation is markedly attenuated by either delapril or TCV-116, an AT1Ra, introduced on postoperative day 1.139 These findings raise the prospect that the number of myoFbs or their Ang IIgenerating activity per cell at sites of repair may be influenced by Ang II. Other studies149,180 have not found an AT1Ra introduced at or soon after coronary artery ligation to influence fibrosis after MI. An explanation for these divergent findings is currently unclear. Each AT1Ra reduced AT1 receptor mRNA expression by 30%; therefore, drug delivery to the site of MI does not seem to be in question. The importance of drug dosage needs to be addressed.
Fibrous tissue formation at sites remote from MI have also been examined in response to these pharmacological interventions. Perindopril given 1 week after MI attenuates the endomyocardial fibrosis that appears in the nonnecrotic segment of the rat left ventricle.138 Captopril commenced at the time of coronary artery ligation prevents the expected fibrosis of noninfarcted left and right ventricle80,181 and the proliferation of fibroblasts and endothelial cells that appears at remote sites 1 and 2 weeks after MI.80 Under these circumstances, captopril prevents the rise in LV end-diastolic pressure that appears in untreated or propranolol-treated rats; captopril also reduces inducibility of ventricular arrhythmias in this model.181 When initiated 3 weeks after MI, well after the tissue repair process has developed, captopril does not prevent fibrosis remote from the infarct site or the rise in ventricular stiffness.62 Losartan prevents fibrosis at remote sites,32,64,179 but not the cellular proliferation that appears.64 Others did not find an inhibition of types I and III collagen mRNA expression at remote sites7,87 and have suggested posttranslational modification in collagen turnover to explain why fibrosis fails to appear at remote sites.7 In the model of cardiac myocyte necrosis associated with chronic Ang II administration, lisinopril attenuates subsequent scarring despite microscopic evidence of myocyte injury.123 Other studies report conflicting results for an AT1Ra with respect to the fibrosis that follows catecholamine-induced myocyte necrosis.113,182
ACEI and AT1Ra prevent the appearance of fibrosis in diverse organs with experimentally induced or naturally occurring tissue injury. These include pericardial fibrosis after pericardiotomy135; tubulointerstitial fibrosis associated with unilateral ureteral obstruction,120,183188 toxic nephropathy,189191 remnant kidney,192195 or renal injury after irradiation196; the cardiovascular sclerosis and glomerulosclerosis that appear in stroke-prone spontaneously hypertensive rats197200; the interstitial pulmonary fibrosis that follows irradiation201203 or monocrotaline administration204; and the subcutaneous fibrous tissue pouch model.205 A more detailed review of Ang II and tissue repair involving systemic organs can be found elsewhere.206
Attenuation of fibrous tissue formation by ACEI and by AT1Ra in particular in diverse organs with various forms of injury supports the importance of local Ang II in promoting fibrosis. Further evidence that this peptide influences collagen turnover has been obtained in cultured adult rat cardiac fibroblasts and myoFbs. In serum-deprived cells, incubation with Ang II in pathophysiological concentrations increases type I collagen mRNA expression and synthesis and reduces the collagenolytic activity of culture medium.168,207209 The importance of Ang IIinduced expression of TGF-ß1 in contributing to this fibrogenic response has been suggested.70,116,206,210
Elevated Circulating Ang II
A role for Ang II, as a local mediator of fibrosis, is suggested
by studies in which circulating Ang II is chronically increased from
either endogenous or exogenous sources. In experimental
models associated with renal ischemia (unilateral in the case
of isolated renal artery stenosis, bilateral in the case of
suprarenal aortic banding), circulating Ang II is increased. Such
models are associated with increased mRNA expression of renal renin,
increased plasma renin activity, and circulating Ang II and
downregulation of Ang II receptors.211213 In
keeping with a role for circulating Ang II in promoting fibrogenesis,
such adverse remodeling is observed in tricuspid and mitral valve
leaflets, the normotensive, nonhypertrophied right and left atria and
right ventricle, and the hypertensive, hypertrophied left ventricle and
is preceded by increased mRNA expression for types I and III collagens
in these models of renovascular
hypertension.5,6,8,213215 Arterioles of
systemic organs likewise undergo a structural remodeling that includes
medial thickening and perivascular
fibrosis.216218
Macrophages, neutrophils, and myoFbs represent the cellular response that precedes the appearance of cardiac fibrosis in these models.94,219 Infrarenal aortic banding, on the other hand, leads to hypertension and left ventricular hypertrophy but not fibrosis of either ventricle,213 further demonstrating that regulation of cardiac myocyte growth is based on hemodynamic factors and not circulating Ang II, whereas fibrous tissue formation is dissociated from hypertrophy and related to this circulating hormone. Myocardial fibrosis in rats with unilateral219221 or bilateral renal ischemia222,223 is prevented by ACEI or AT1Ra.
Chronic infusion of Ang II by osmotic minipump leads to fibrosis of atria and ventricles, increased adventitial collagen of the normotensive pulmonary artery and hypertensive aorta, and systemic organ fibrosis.19,121,224 Fibrosis is initially preceded by increased mRNA expression of fibronectin on day 3 and subsequently types I and III collagens and TGF-ß1, each of which is related to proliferating fibroblast-like cells (not myocytes) located at sites of subsequent fibrosis in each ventricle.225,226 Losartan, given in doses that either did or did not prevent an increase in arterial pressure, abrogated these responses. This was not the case for prazosin or hydralazine, which prevented hypertension, again confirming that hemodynamic factors are not involved in promoting fibrosis.225,226 Potential mechanisms involved in the fibrogenic response associated with chronic elevations in Ang II have been reviewed elsewhere.227
Ang II and Other Modulators of Repair
Although Ang II is intimately involved in promoting tissue repair,
a broader view of its relationship to other regulatory signals evoked
at sites of injury is in order (see Fig 4
). Ang II invokes the elaboration of
stimulators and inhibitors of fibrogenesis in what
constitutes a reciprocal regulation of repair.228
The relative preponderance of inhibitors versus stimulators
determines healing. In a biological economy of action, these signals
likewise regulate immediate homeostatic responses after injury.
Stimulators of repair, such as Ang II, aldosterone,
catecholamines, and ETs, promote coagulation and
platelet aggregation, vasoconstriction, tachycardia and
increased contractility, and renal sodium retention.
Inhibitors, such as NO, BK, PGs, natriuretic
peptides, dopamine, and glucocorticoids, have opposing effects on
homeostasis and repair. The relative preponderance and potency of
stimulators versus inhibitors determine overall responses.
In advanced heart failure, for example, circulating levels of
natriuretic peptides, Ang II, aldosterone, and
ETs are each increased. The potency of RAAS effector hormones
supersedes natriuretic peptides, with sodium retention and
cardiac remodeling the final result. A discussion of the interplay that
exists between Ang II and several of these stimulators and
inhibitors is provided, focusing on the fibrogenic
component of repair.
|
A close relationship between Ang II generated at sites of injury and expression of the profibrotic cytokine represented by the TGF-ß family of peptides was suggested earlier. Binding of TGF-ß1 with its receptors on fibroblasts, for example, regulates their expression of type I collagen and TIMP and favors fibrous tissue formation,85,229 a response abrogated in injured tissue by ACEI or AT1Ra. Ang II and TGF-ß1 each regulate expression of ET by fibroblast-like cells.230234 ET1 and ET3 both regulate fibroblast collagen turnover via ETA and ETB receptor binding.235237 Antagonists of either the ETA or ETA and ETB receptors prevent organ fibrosis.238,239
Inhibitors of fibrous tissue formation express their
influence on collagen turnover by reducing collagen synthesis and/or
enhancing its degradation. iNOS is expressed by macrophages
activated by cytokines (eg,
-interferon) through
transcription of genes encoding for iNOS; large amounts of NO are
generated for hours at sites of injury.240242
NO and other nitrogen oxides produced by activated
macrophages are cytostatic and
cytotoxic.243 A short-term (hours) infusion of
Ang II is associated with a rise in cardiac lymph cGMP,
representing a release of NO from its constitutive form
found in coronary vascular endothelium; an
associated escape of macromolecules follows.74
This increase in vascular permeability and appearance of proteins in
the cardiac interstitial space leads to subsequent vascular
and interstitial fibrosis. However, when L-NAME, a specific
inhibitor of the oxidative L-arginine deiminase
pathway and NOS activity, is administered together with Ang II to
prevent macromolecular escape, myocardial fibrosis still
appears.244 Such a regimen augments and
accelerates the appearance of cardiac fibrosis, in keeping with the
removal of NO as an inhibitor of fibroblast collagen
turnover and fibrosis.245 Removal of NO favoring
fibrous tissue formation occurs naturally at sites of repair through
expression of TGF-ß1, which inhibits iNOS mRNA
translation while increasing iNOS protein
degradation.240
Chronic administration of L-NAME alone leads to coronary vascular remodeling, including an increased wall thicknessto-lumen ratio and perivascular fibrosis, and the gradual appearance of arterial hypertension over the course of several weeks.246 These iterations in coronary vascular structure are not related to this rise in arterial pressure, as evidenced by rats treated with L-NAME and hydralazine in combination, who remained normotensive, or rats receiving a small dose of L-NAME that did not lead to hypertension. In each case, coronary remodeling still occurred. The importance of unopposed, local Ang II generation in promoting this remodeling is therefore suggested, and increased ACE activity is present in remodeled intramyocardial coronary arteries seen with long-term blockade of NO synthesis.247 ACEI prevents such L-NAMEassociated remodeling by reducing local concentrations of Ang II at sites of fibrosis.
BK, like NO, is linked to inflammatory responses. BK is rapidly degraded; however, its effect is expressed via the release of other substances, such as prostaglandins.248 During the acute inflammatory phase that follows MI on days 1 and 4, the release of PGE2 is markedly increased by administration of BK.249 Prostaglandin synthesis has been demonstrated in various mesenchymal cells, including endothelial cells, squamous epithelium of visceral and parietal pericardium, pleura, and peritoneum,250,251 and fibroblasts of various organs.252,253 Fibroblast-like cells isolated from infarcted tissue 7 days after coronary ligation demonstrated increased cyclooxygenase activity and PGE2 production compared with fibroblasts of noninfarcted tissue.254
Ang II, BK, and PGE2 are released by cells involved in tissue repair. The expression of angiotensinogen mRNA, measured on day 5 after MI, is increased in the left ventricle.255 This precedes the early morphological evidence of fibrillar collagen accumulation that appears on day 7.33 Ang II content of infarcted tissue is increased compared with remote sites; this response is prevented by delapril.139 At week 4 after MI, and long after the inflammatory phase has resolved, BK-induced release of PGE2 from the heart remains increased.249 Even as late as 12 weeks after MI, microsomes prepared from infarcted tissue demonstrate enhanced arachidonic acid metabolism.256
| A Paradigm of Tissue Repair |
|---|
|
|
|---|
-interferon, which serves to
activate macrophages that have invaded the
fibrin-fibronectin meshwork from the circulation and local sites. Once
activated, macrophages express the gene encoding for
iNOS and produce NO, which is related to their programmed cell death
(apoptosis), including the macrophages that produce
it.257259 Activated macrophages
likewise express inducible cyclooxygenase that
leads to their production of PGs. A phenotype
conversion of macrophages is involved, given that inactive
macrophages do not express ACE. This adaptation of
macrophages results in their acquiring functional activity that
includes expression of angiotensinogen, ACE, and cathepsin
G and their ability to generate Ang II de
novo.40,260 In an autocrine manner,
macrophage-derived Ang II stimulates expression of
TGF-ß1, which favors the recruitment of
pluripotent interstitial fibroblasts and their conversion
to the myoFb phenotype on day 4 after injury; myoFb
proliferation follows. TGF-ß1 also serves to
suppress the inflammatory cell response favoring collagen formation.
ACEI or AT1Ra introduced at the time of repair or
within the first 48 hours could interfere with the ultimate appearance
of fibrous tissue by abrogating this first phase of Ang II generation
and its important functions in cell-cell signaling and
TGF-ß1 formation.
|
Like transformed macrophages, myoFbs express components
requisite to de novo Ang II generation. This subsequent source of Ang
II has an autocrine function that stimulates expression of
TGF-ß1, and it is this cytokine that
determines collagen turnover at sites of repair and remote sites (Fig 5
) through transcriptional regulation of fibrillar collagens and TIMPs.
Fibrous tissue accumulation at both sites now commences.
MyoFb-generated Ang II has several paracrine functions that serve to
stimulate endothelial cells of the neovasculature to
elaborate NO, BK, PGs, ETs, steroids, and
TIMP-1,261 each of which likewise contributes to
inflammatory and fibrogenic events. The nature of these steroids is not
fully understood. It has been suggested that
endothelial cells elaborate
aldosterone,262,263 whereas
spironolactone, an aldosterone receptor
antagonist, inhibits angiogenesis.264
The potential for local steroidogenesis at sites of repair and the
influence of such steroids on healing remains to be examined.
Once fibrous tissue has been deposited and the extracellular matrix remodeled (eg, wound closure of skin), myoFbs are reduced in number and eventually disappear through apoptosis, or programmed cell death.109 An activation of MMPs and absence of Ang II and TGF-ß1 may actually lead to a regression of fibrosis, as is the case in skin. Persistence of myoFbs or a particular subpopulation of myoFbs, with continued expression of Ang II and TGF-ß1, is accompanied by low-grade collagen turnover, as is the case for the permanent scar that appears at the site of MI.85,86 Under circumstances in which myoFbs persist or a subpopulation increases in number, a progressive fibrosis will result.103 The pathophysiology accounting for regressive, persistent, and progressive fates of fibrosis remains to be elucidated. Insights into these various events should shed light on the development of cardioprotective and reparative strategies. In addition, a broader understanding of fibrillar collagen expression265 and the tissue repair paradigm119 may provide other means by which to interfere with unwanted fibrosisa final pathway to cardiac failure.
| Ang II, DD, and the Clinical Vignette Revisited |
|---|
|
|
|---|
|
DD of either the right or left ventricle, either form of which has been demonstrated to be of importance in patients with heart failure,50,269 is related to factors extrinsic to the ventricular chamber (eg, right and left heart interaction, fibrosed pericardium) and to those intrinsic to its myocardium (eg, fibrous tissue, abnormalities in sarcoplasmic calcium uptake), which can influence relaxation and passive stiffness. The multiple lines of evidence reviewed in this report would suggest that a broader perspective of DD is warranted. Whether expressed in the form of a macroscopic scar after MI or as microscopic fibrosis, such as appears remote from an MI or with chronic RAAS activation, fibrous tissue has the potential for contractile behavior, based on the presence of myoFbs.
In hopes of shedding more light on this subject, earlier observations pertaining to administration of Ang II or ACEI on DD in experimental animals and diseased human myocardium are briefly reviewed. These informative studies were undertaken in view of the early recognition of a relationship between increased ACE activity and hypertrophy found in a rat model of suprarenal aortic banding. It is now appreciated that the localization of high-density ACE binding (and activity) is confined to sites of fibrosis that appear in both the hypertrophied ventricle and nonhypertrophied ventricle and atria, pericardium, and systemic organs. ACE binding is independent of the pattern of hypertrophy (concentric versus eccentric), hemodynamic factors, and circulating Ang II.
In isolated normal rat hearts, in which left ventricular diastolic volume was experimentally fixed (an isovolumic preparation), intracoronary infusion of Ang II did not influence end-diastolic pressure.212 This same preparation was used to study the hypertrophied left ventricle observed in rats 8 weeks after suprarenal aortic banding. A reactive and reparative fibrosis coincident with high-density ACE binding and myoFbs at these sites (see above) is likewise expected. Administration of Ang II led to a 50% increase in filling pressure of the isovolumic ventricle, which could be prevented by losartan but not an AT2 receptor antagonist.212 This finding supports my contention that fibrous tissue contraction, as well as proposed alterations in cardiac myocyte calcium homeostasis, can contribute to DD.
In patients with severe LVH, hypertension, and elevated end-diastolic pressure, in whom myocardial fibrosis is expected,270,271 a 30-minute left coronary artery infusion of enalaprilat at a dose that did not affect heart rate or systemic vascular resistance led to an acute fall in filling pressure.272 A similar intracoronary infusion of enalaprilat for 15 minutes led to an acute reduction in left ventricular end-diastolic pressure and improvement in diastolic distensibility in patients with LVH and significant aortic valvular stenosis.273 Fibrosis is a well-recognized accompaniment of the structural remodeling found in aortic stenosis.274276 Benazeprilat given intravenously led to an acute reduction in end-diastolic pressure and diastolic wall stress in patients with coronary artery disease and previous transmural MI, and this response was noted in asymptomatic and symptomatic patients with cardiac failure.277
Collectively, these findings serve to suggest that the salutary response to ACEI in cardiac failure may include an improvement in DD and may be related to relaxation of fibrous tissue and the tension it exerts within the fibrosed and hypertrophied myocardium.
| Summary and Future Directions |
|---|
|
|
|---|
| Selected Abbreviations and Acronyms |
|---|
|
| References |
|---|
|
|
|---|
2. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685691.[Abstract]
3. Cotran RS, Kumar V, Robbins SL. Robbins' Pathologic Basis of Disease. 4th ed. Philadelphia, Pa: WB Saunders; 1989.
4.
Beltrami CA, Finato N, Rocco M, Feruglio GA,
Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P.
Structural basis of end-stage failure in ischemic
cardiomyopathy in humans. Circulation. 1994;89:151163.
5. Doering CW, Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams C, Weber KT. Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res. 1988;22:686695.[Medline] [Order article via Infotrieve]
6.
Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG,
Weber KT. Fibrillar collagen and myocardial stiffness in the intact
hypertrophied rat left ventricle. Circ Res. 1989;64:10411050.
7. Dixon IMC, Ju H, Jassal DS, Peterson DJ. Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol Cell Biochem. 1996;165:3145.[Medline] [Order article via Infotrieve]
8.
Averill DB, Ferrario CM, Tarazi RC, Sen S, Bajbus R.
Cardiac performance in rats with renal hypertension. Circ
Res. 1976;38:280288.
9. Bing OHL, Matsushita S, Fanburg BL, Levine HJ. Mechanical properties of rat cardiac muscle during experimental hypertrophy. Circ Res. 1971;28:233245.
10.
Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis:
functional significance and regulatory factors. Cardiovasc
Res. 1993;27:341348.
11. Weber KT, Anversa P, Armstrong PW, Bauer JH, Brilla CG, Burnett JC, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV, Mendelsohn FAO, Motz WH, Mulvaney MJ. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:316.[Abstract]
12.
Brilla CG, Janicki JS, Weber KT. Cardioreparative
effects of lisinopril in rats with genetic hypertension and
left ventricular hypertrophy.
Circulation. 1991;83:17711779.
13.
Pouleur H, Rousseau MF, van Eyll C, Stoleru L,
Hayashidi W, Udelson JA, Dolan N, Kinan D, Gallagher P, Ahn S, Benedict
CR, Yusuf S, Konstam M, for the SOLVD Investigators. Effects of
long-term enalapril therapy on left ventricular
diastolic properties in patients with depressed ejection
fraction.. Circulation. 1993;88:481491.
14. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:14291435.[Abstract]
15.
Weber KT, Brilla CG. Pathological
hypertrophy and cardiac interstitium: fibrosis and
renin-angiotensin-aldosterone system.
Circulation. 1991;83:18491865.
16.
Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw
B, Delcayre C. Increased cardiac types I and III collagen mRNAs in
aldosterone-salt hypertension. Hypertension. 1994;24:3036.
17. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest. 1994;93:25782583.
18.
Young M, Head G, Funder J. Determinants of cardiac
fibrosis in experimental hypermineralocorticoid states. Am J
Physiol. 1995;269:E657E662.
19.
Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and
great vessels in response to angiotensin II or
aldosterone infusion. Cardiovasc Res. 1997;35:138147.
20.
Wollert KC, Studer R, von Bülow B, Drexler H.
Survival after myocardial infarction in the rat: role of tissue
angiotensin-converting enzyme inhibition.
Circulation. 1994;90:24572467.
21.
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for
the CONSENSUS Trial Study Group. Hormones regulating
cardiovascular function in patients with severe
congestive heart failure and their relation to mortality.
Circulation. 1990;82:17301736.
22.
Strain JE, Grose RM, Factor SM, Fisher JD. Results of
endomyocardial biopsy in patients with spontaneous
ventricular tachycardia but without apparent
structural heart disease. Circulation. 1983;68:11711181.
23. Messerli FH, Grodzicki T. Hypertension, left ventricular hypertrophy, ventricular arrhythmias and sudden death. Eur Heart J. 1992;13(suppl D):6669.
24. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669677.[Abstract]
25. Rouleau JL, de Champlain J, Klein M, Bichet D, Moyé L, Packer M, Dagenais GR, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy TE, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Hamm P, Pfeffer MA. Activation of neurohormonal systems in postinfarction left ventricular hypertrophy. J Am Coll Cardiol. 1993;22:390398.[Abstract]
26.
Johnston CI. Tissue angiotensin
converting enzyme in cardiac and vascular hypertrophy,
repair, and remodeling. Hypertension. 1994;23:258268.
27. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry. 1989;28:53115318.[Medline] [Order article via Infotrieve]
28. Studer R, Reinecke H, Müller B, Holtz J, Just H, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart: quantification by competitive RNA polymerase chain reaction. J Clin Invest. 1994;94:301310.
29. Hokimoto S, Yasue H, Fujimoto K, Sakata R, Miyamoto E. Increased angiotensin converting enzyme activity in left ventricular aneurysm of patients after myocardial infarction. Cardiovasc Res. 1995;29:664669.[Medline] [Order article via Infotrieve]
30.
Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ.
Tissue-specific activation of cardiac angiotensin
converting enzyme in experimental heart failure. Circ Res. 1991;69:475482.
31. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility, and relaxation. J Clin Invest. 1990;86:19131920.
32.
Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J,
Riede UN, Drexler H. Comparative effects of chronic
angiotensin-converting enzyme inhibition and
angiotensin II type 1 receptor blockade on cardiac
remodeling after myocardial infarction in the rat.
Circulation. 1994;89:22732282.
33.
Sun Y, Cleutjens JPM, Diaz-Arias AA, Weber KT.
Cardiac angiotensin converting enzyme and myocardial
fibrosis in the rat. Cardiovasc Res. 1994;28:14231432.
34. Ou R, Sun Y, Ganjam VK, Weber KT. In situ production of angiotensin II by fibrosed rat pericardium. J Mol Cell Cardiol. 1996;28:13191327.[Medline] [Order article via Infotrieve]
35. Sappino AP, Schürch W, Gabbiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest. 1990;63:144161.[Medline] [Order article via Infotrieve]
36. Skalli O, Schürch W, Seemayer T, Lagacé R, Montandon D, Pittet B, Gabbiani G. Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest. 1989;60:275285.[Medline] [Order article via Infotrieve]
37.
Meggs LG, Coupet J, Huang H, Cheng W, Li P, Capasso
JM, Homcy CJ, Anversa P. Regulation of angiotensin II
receptors on ventricular myocytes after myocardial
infarction in rats. Circ Res. 1993;72:11491162.
38. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997;29:859870.[Medline] [Order article via Infotrieve]
39.
Yamada T, Horiuchi M, Dzau VJ.
Angiotensin II type 2 receptor mediates programmed cell
death. Proc Natl Acad Sci U S A. 1996;93:156160.
40.
Klickstein LB, Kaempfer CE, Wintroub BU. The
granulocyte-angiotensin system: angiotensin
I-converting activity of cathepsin G. J Biol Chem. 1982;257:1504215046.
41. Weber KT, Sun Y, Katwa LC, Cleutjens JPM. Connective tissue: a metabolic entity? J Mol Cell Cardiol. 1995;27:107120.[Medline] [Order article via Infotrieve]
42. Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experiment with 250 patients. Am J Cardiol. 1967;20:457464.[Medline] [Order article via Infotrieve]
43. Weber KT, Janicki JS, Russell RO, Rackley CE. Identification of high risk subsets of acute myocardial infarction. Am J Cardiol. 1978;41:197203.[Medline] [Order article via Infotrieve]
44. Forrester JS, Diamond G, McHugh TJ, Swan HJ. Filling pressures in the right and left sides of the heart in acute myocardial infarction: a reappraisal of central-venous-pressure monitoring. N Engl J Med. 1971;285:190193.
45. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol. 1988;62:25A30A.[Medline] [Order article via Infotrieve]
46. Xie G-Y, Berk MR, Smith MD, Gurley JC, DeMaria AN. Prognostic value of Doppler transmitral flow patterns in patients with congestive heart failure. J Am Coll Cardiol. 1994;24:132139.[Abstract]
47. Pinamonti B, Di Lenarda A, Sinagra G, Camerini F, and the Heart Muscle Disease Study Group. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. J Am Coll Cardiol. 1993;22:808815.[Abstract]
48. Weber KT, Janicki JS. The dynamics of ventricular contraction: force, length, and shortening. Fed Proc. 1980;39:188195.[Medline] [Order article via Infotrieve]
49. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med. 1991;325:15571564.[Medline] [Order article via Infotrieve]
50.
Yu CM, Sanderson JE, Chan S, Yeung L, Hung YT, Woo
KS. Right ventricular diastolic dysfunction in
heart failure. Circulation. 1996;93:15091514.
51. Weber KT. Cardiopulmonary exercise testing and the evaluation of systolic dysfunction. In: Wasserman K, ed. Exercise Gas Exchange in Heart Disease. Armonk, NY: Futura; 1996:5562.
52. Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol. 1991;17:10651072.[Abstract]
53. Weber KT, Janicki JS. Lactate production during maximal and submaximal exercise in patients with chronic heart failure. J Am Coll Cardiol. 1985;6:717724.[Abstract]
54. Wilson JR, Ferraro N. Exercise intolerance in patients with chronic left heart failure: relation to oxygen transport and ventilatory abnormalities. Am J Cardiol. 1983;51:13581363.[Medline] [Order article via Infotrieve]
55.
Francis GS, Benedict C, Johnstone DE, Kirlin PC,
Nicklas J, Liang C, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of
neuroendocrine activation in patients with left ventricular
dysfunction with and without congestive heart failure: a substudy of
the Studies of Left Ventricular Dysfunction (SOLVD).
Circulation. 1990;82:17241729.
56.
Villarreal D, Freeman RH, Johnson RA. Neurohormonal
modulators and sodium balance in experimental heart failure.
Am J Physiol. 1993;264:H1187H1193.
57. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol. 1993;71(suppl A):3A11A.
58.
Bing OHL, Fanburg BL, Brooks WW, Matsushita S. The
effect of the lathyrogen ß-amino proprionitrile (BAPN) on the
mechanical properties of experimentally hypertrophied rat cardiac
muscle. Circ Res. 1978;43:632637.
59. Thiedemann KU, Holubarsch C, Medugorac I, Jacob R. Connective tissue content and myocardial stiffness in pressure overload hypertrophy: a combined study of morphologic, morphometric, biochemical and mechanical parameters. Basic Res Cardiol. 1983;78:140155.[Medline] [Order article via Infotrieve]
60.
Hess OM, Schneider J, Koch R, Bamert C, Grimm J,
Krayenbuehl HP. Diastolic function and myocardial structure
in patients with myocardial hypertrophy: special reference
to normalized viscoelastic data. Circulation. 1981;63:360371.
61.
Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG,
Bing OHL. Myocardial fibrosis and stiffness with
hypertrophy and heart failure in the spontaneously
hypertensive rat. Circulation. 1995;91:161170.
62.
Litwin SE, Litwin CM, Raya TE, Warner AL, Goldman S.
Contractility and stiffness of noninfarcted
myocardium after coronary ligation in rats: effects
of chronic angiotensin converting enzyme inhibition.
Circulation. 1991;83:10281037.
63. Pelouch V, Dixon IMC, Golfman L, Beamish RE, Dhalla NS. Role of extracellular matrix proteins in heart function. Mol Cell Biochem. 1993;129:101120.[Medline] [Order article via Infotrieve]
64. Smits JFM, van Krimpen C, Schoemaker RG, Cleutjens JPM, Daemen MJAP. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol. 1992;20:772778.[Medline] [Order article via Infotrieve]
65. Pfeffer JM, Pfeffer MA, Fishbein MC, Froehlich ED. Cardiac function and morphology with aging in the spontaneously hypertensive rat. Am J Physiol. 1979;6:H461H468.
66.
Boluyt MO, O'Neill L, Meredith AL, Bing OHL, Brooks
WW, Conrad CH, Crow MT, Lakatta EG. Alterations in cardiac gene
expression during the transition from stable hypertrophy to
heart failure: marked upregulation of genes encoding extracellular
matrix components. Circ Res. 1994;75:2332.
67. Bing OHL, Sen S, Conrad CH, Brooks WW. Myocardial function structure and collagen in the spontaneously hypertensive rat: progression from compensated hypertrophy to haemodynamic impairment. Eur Heart J. 1984;5(suppl F):4352.
68. Iwai N, Shimoike H, Kinoshita M. Genes up-regulated in hypertrophied ventricle. Biochem Biophys Res Commun. 1995;209:527534.[Medline] [Order article via Infotrieve]
69. Booz GW, Baker KM. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res. 1995;30:537543.[Medline] [Order article via Infotrieve]
70. Sharma HS, van Heugten HAA, Goedbloed MA, Verdouw PD, Lamers JMJ. Angiotensin II induced expression of transcription factors precedes increase in transforming growth factor-ß1 mRNA in neonatal cardiac fibroblasts. Biochem Biophys Res Commun. 1994;205:105112.[Medline] [Order article via Infotrieve]
71.
Puri PL, Avantaggiati ML, Burgio VL, Chirillo P,
Collepardo D, Natoli G, Balsano C, Levrero M. Reactive oxygen
intermediates angiotensin II-induced c-Jun · c-Fos
heterodimer DNA binding activity and proliferative hypertrophic
responses in myogenic cells. J Biol Chem. 1995;270:2212922134.
72. Crabos M, Roth M, Hahn AWA, Erne P. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. J Clin Invest. 1994;93:23722378.
73. Reddy HK, Campbell SE, Janicki JS, Zhou G, Weber KT. Coronary microvascular fluid flux and permeability: influence of angiotensin II, aldosterone and acute arterial hypertension. J Lab Clin Med. 1993;121:510521.[Medline] [Order article via Infotrieve]
74. Sigusch HH, Ou R, Katwa LC, Campbell SE, Ganjam VK, Reddy HK, Weber KT. Angiotensin-II-induced increase in transcoronary protein clearance: role of hypertension vs. nitric oxide or cyclo-oxygenase products. Cardiovasc Res. 1995;30:291298.[Medline] [Order article via Infotrieve]
75.
Michael LH, Hunt JR, Lewis RM, Entman ML. Myocardial
ischemia: platelet and thromboxane
concentrations in cardiac lymph and the effects of ibuprofen and
prostacyclin. Circ Res. 1986;59:4955.
76.
Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K.
Role of locally formed angiotensin II and bradykinin in the
reduction of myocardial infarct size in dogs. Cardiovasc
Res. 1993;27:334340.
77. Hashimoto K, Hirose M, Furukawa K, Hayakawa H, Kimura E. Changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. Jpn Heart J. 1977;18:679689.[Medline] [Order article via Infotrieve]
78. Bissell MJ, Hall HG, Parry G. How does the extracellular matrix direct gene expression? J Theor Biol. 1982;99:3168.[Medline] [Order article via Infotrieve]
79. Volders PGA, Willems IEMG, Cleutjens JPM, Arends J-W, Havenith MG, Daemen MJAP. Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol. 1993;25:13171323.[Medline] [Order article via Infotrieve]
80. van Krimpen C, Smits JFM, Cleutjens JPM, Debets JJ, Schoemaker RG, Struyker-Boudier HA, Bosman FT, Daemen MJ. DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat heart: effects of captopril. J Mol Cell Cardiol. 1991;23:12451253.[Medline] [Order article via Infotrieve]
81. Sekita S, Katagiri T, Sasai Y, Takeda K. Studies on collagen in the experimental myocardial infarction. Jpn Circ J. 1985;49:171178.[Medline] [Order article via Infotrieve]
82. Cleutjens JPM, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27:12811292.[Medline] [Order article via Infotrieve]
83. Knowlton AA, Connelly CM, Romo GM, Mamuya W, Apstein CS, Brecher P. Rapid expression of fibronectin in the rabbit heart after myocardial infarction with and without reperfusion. J Clin Invest. 1992;89:10601068.
84. Cleutjens JPM, Verluyten MJA, Smits JFM, Daemen MJAP. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147:325338.[Abstract]
85.
Willems IEMG, Havenith MG, De Mey JGR, Daemen MJAP.
The
-smooth muscle actin-positive cells in healing human
myocardial scars. Am J Pathol. 1994;145:868875.[Abstract]
86. Sun Y, Weber KT. Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol. 1996;28:851858.[Medline] [Order article via Infotrieve]
87. Hanatani A, Yoshiyama M, Kim S, Omura T, Toda I, Akioka K, Teragaki M, Takeuchi K, Iwao H, Takeda T. Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. J Mol Cell Cardiol. 1995;27:19051914.[Medline] [Order article via Infotrieve]
88. Whittaker P. Unravelling the mysteries of collagen and cicatrix after myocardial infarction. Cardiovasc Res. 1996;31:1927.[Medline] [Order article via Infotrieve]
89. Jugdutt BI, Amy RWM. Healing after myocardial infarction in the dog: changes in infarct hydroxyproline and topography. J Am Coll Cardiol. 1986;7:91102.[Abstract]
90.
McCormick RJ, Musch TI, Bergman BC, Thomas DP.
Regional differences in LV collagen accumulation and mature
cross-linking after myocardial infarction in rats. Am J
Physiol. 1994;266:H354H359.
91. Pelouch V, Dixon IMC, Sethi R, Dhalla NS. Alteration of collagenous protein profile in congestive heart failure secondary to myocardial infarction. Mol Cell Biochem. 1993;129:121131.[Medline] [Order article via Infotrieve]
92. McCulloch CAG, Bordin S. Role of fibroblast subpopulations in periodontal physiology and pathology. J Periodont Res. 1991;26:144154.[Medline] [Order article via Infotrieve]
93. Vracko R, Thorning D. Contractile cells in rat myocardial scar tissue. Lab Invest. 1991;65:214227.[Medline] [Order article via Infotrieve]
94. Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol. 1995;27:15451560.[Medline] [Order article via Infotrieve]
95. Leslie KO, Taatjes DJ, Schwarz J, vonTurkovich M, Low RB. Cardiac myofibroblasts express alpha smooth muscle actin during right ventricular pressure overload in the rabbit. Am J Pathol. 1991;139:207216.[Abstract]
96. Bishop JE, Rhodes S, Laurent GJ, Low RB, Stirewalt WS. Increased collagen synthesis and decreased collagen degradation in right ventricular hypertrophy induced by pressure overload. Cardiovasc Res. 1994;28:15811585.[Medline] [Order article via Infotrieve]
97. Majno G. The story of the myofibroblasts. Am J Surg Pathol. 1979;3:535542.[Medline] [Order article via Infotrieve]
98. Gabbiani G, Hirschel BJ, Ryan GB, Statkov PR, Majno G. Granulation tissue as a contractile organ: a study of structure and function. J Exp Med. 1972;135:719734.[Abstract]
99.
Desmoulière A, Geinoz A, Gabbiani F, Gabbiani
G. Transforming growth factor-ß1 induces
-smooth muscle actin
expression in granulation tissue myofibroblasts and in quiescent and
growing cultured fibroblasts. J Cell Biol. 1993;122:103111.
100. Thompson NL, Bazoberry F, Speir EH, Casscells W, Ferrans VJ, Flanders KC, Kondaiah P, Geiser AG, Sporn MB. Transforming growth factor beta-1 in acute myocardial infarction in rats. Growth Factors. 1988;1:9199.[Medline] [Order article via Infotrieve]
101. Casscells W, Bazoberry F, Speir E, Thompson N, Flanders K, Kondaiah P, Ferrans VJ, Epstein SE, Sporn M. Transforming growth factor-ß1 in normal heart and in myocardial infarction. Ann N Y Acad Sci. 1990;593:148160.[Medline] [Order article via Infotrieve]
102. Riches DWH. Macrophage involvement in wound repair, remodeling, and fibrosis. In: Clark RAF, ed. The Molecular and Cellular Biology of Wound Repair. 2nd ed. New York, NY: Plenum Press; 1996:95141.
103. Zhang G, Moorhead PJ, el Nahas AM. Myofibroblasts and the progression of experimental glomerulonephritis. Exp Nephrol. 1995;3:308318.[Medline] [Order article via Infotrieve]
104.
Singer II, Kawka DW, Kazazis DM, Clark RAF. In vivo
co-distribution of fibronectin and actin fibers in granulation tissue:
immunofluorescence and electron microscope studies
of the fibronexus at the myofibroblast surface. J Cell Biol. 1984;98:20912106.
105. Bishop J, Greenbaum J, Gibson D, Yacoub M, Laurent GJ. Enhanced deposition of predominantly type I collagen in myocardial disease. J Mol Cell Cardiol. 1990;22:11571165.[Medline] [Order article via Infotrieve]
106.
Mukherjee D, Sen S. Collagen phenotypes during
development and regression of myocardial hypertrophy in
spontaneously hypertensive rats. Circ Res. 1990;67:14741480.
107.
Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM,
Bashey RI. Collagen remodeling of the pressure-overloaded,
hypertrophied nonhuman primate myocardium. Circ
Res. 1988;62:757765.
108.
Darby I, Skalli O, Gabbiani G.
-Smooth muscle
actin is transiently expressed by myofibroblasts during experimental
wound healing. Lab Invest. 1990;63:2129.[Medline]
[Order article via Infotrieve]
109. Desmoulière A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol. 1995;146:5666.[Abstract]
110. Bellamy COC, Malcomson RDG, Harrison DJ, Wyllie AH. Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol. 1995;6:316.[Medline] [Order article via Infotrieve]
111. Border WA, Ruoslahti E. Transforming growth factor-ß in disease: the dark side of tissue repair. J Clin Invest. 1992;90:17.
112. Lawrence WT, Diegelmann RF. Growth factors in wound healing. Clin Dermatol. 1994;12:157169.[Medline] [Order article via Infotrieve]
113.
Omura T, Kim S, Takeuchi K, Iwao H, Takeda T.
Transforming growth factor ß1 and extracellular
matrix gene expression in isoprenaline induced cardiac
hypertrophy: effects of inhibition of the
renin-angiotensin system. Cardiovasc Res. 1994;28:18351842.
114. Chua CC, Chua BHL, Zhao ZY, Krebs C, Diglio C, Perrin E. Effect of growth factors on collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res. 1991;26:271281.[Medline] [Order article via Infotrieve]
115.
Sadoshima J, Izumo S. Molecular characterization of
angiotensin II-induced hypertrophy of cardiac
myocytes and hyperplasia of cardiac fibroblasts: critical role of the
AT1 receptor subtype. Circ Res. 1993;73:413423.
116. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-ß1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:19471958.[Medline] [Order article via Infotrieve]
117.
Everett AD, Tufro-McReddie A, Fisher A, Gomez RA.
Angiotensin receptor regulates cardiac
hypertrophy and transforming growth factor-ß1
expression. Hypertension. 1994;23:587592.
118. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, Bariéty J, Michel J-B. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest. 1994;70:286294.[Medline] [Order article via Infotrieve]
119. Wardle N. Glomerulosclerosis: the final pathway is clarified, but can we deal with the triggers? Nephron. 1996;73:17.[Medline] [Order article via Infotrieve]
120. Pimentel JL Jr, Martinez-Maldonado M, Wilcox JN, Wang S, Luo C. Regulation of renin-angiotensin system in unilateral ureteral obstruction. Kidney Int. 1993;44:390400.[Medline] [Order article via Infotrieve]
121. Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med. 1993;122:395403.[Medline] [Order article via Infotrieve]
122. Sun Y, Weber KT. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J Lab Clin Med. 1993;122:404411.[Medline] [Order article via Infotrieve]
123. Sun Y, Ratajska A, Weber KT. Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med. 1995;126:95101.[Medline] [Order article via Infotrieve]
124. Sun Y, Ratajska A, Weber KT. Bradykinin receptor and tissue ACE binding in myocardial fibrosis: response to chronic angiotensin II or aldosterone administration in rats. J Mol Cell Cardiol. 1995;27:813822.[Medline] [Order article via Infotrieve]
125. Sun Y, Diaz-Arias AA, Weber KT. Angiotensin-converting enzyme, bradykinin and angiotensin II receptor binding in rat skin, tendon and heart valves: an in vitro quantitative autoradiographic study. J Lab Clin Med. 1994;123:372377.[Medline] [Order article via Infotrieve]
126. Allen AM, Yamada H, Mendelsohn FAO. In vitro autoradiographic localization of binding to angiotensin receptors in the rat heart. Int J Cardiol. 1990;28:2533.[Medline] [Order article via Infotrieve]
127.
Yamada H, Fabris B, Allen AM, Jackson B,
Johnston CI, Mendelsohn FAO. Localization of angiotensin
converting enzyme in rat heart. Circ Res. 1991;68:141149.
128. Pinto JE, Viglione P, Saavedra JM. Autoradiographic localization and quantification of rat heart angiotensin converting enzyme. Am J Hypertens. 1991;4:321326.[Medline] [Order article via Infotrieve]
129. Danilov SM, Faerman AI, Printseva OY, Martynov AV, Sakharov IY, Trakht IN. Immunohistochemical study of angiotensin-converting enzyme in human tissues using monoclonal antibodies. Histochemistry. 1987;87:487490.[Medline] [Order article via Infotrieve]
130. Katwa LC, Ratajska A, Cleutjens JPM, Sun Y, Zhou G, Lee SJ, Weber KT. Angiotensin converting enzyme and kininase-II-like activities in cultured valvular interstitial cells of the rat heart. Cardiovasc Res. 1995;29:5764.[Medline] [Order article via Infotrieve]
131.
Nakajima Y, Miyazono K, Kato M, Takase M, Yamagishi T,
Nakamura H. Extracellular fibrillar structure of latent TGFß
binding protein-1: role in TGFß-dependent
endothelial-mesenchymal transformation during
endocardial cushion tissue formation in mouse embryonic heart. J
Cell Biol. 1997;136:193204.
132. Potts JD, Vincent EB, Runyan RB, Weeks DL. Sense and antisense TGFß3 mRNA levels correlate with cardiac valve induction. Dev Dyn. 1992;193:340345.[Medline] [Order article via Infotrieve]
133. Katwa LC, Tyagi SC, Campbell SE, Lee SJ, Cicila GT, Weber KT. Valvular interstitial cells express angiotensinogen, cathepsin D, and generate angiotensin peptides. Int J Biochem Cell Biol. 1996;28:807821.[Medline] [Order article via Infotrieve]
134. Weber KT, Sun Y, Katwa LC. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol. 1997;29:3142.[Medline] [Order article via Infotrieve]
135.
Sun Y, Weber KT. Angiotensin II receptor
binding following myocardial infarction in the rat. Cardiovasc
Res. 1994;28:16231628.
136.
Filip DA, Radu A, Simionescu M.
Interstitial cells of the heart valves possess
characteristics similar to smooth muscle cells. Circ Res. 1986;59:310320.
137. Sims DE. The pericyte: a review. Tissue Cell. 1986;18:153174.[Medline] [Order article via Infotrieve]
138.
Michel J-B, Lattion A-L, Salzmann J-L, Cerol ML,
Philippe M, Camilleri J-P, Corvol P. Hormonal and cardiac effects of
converting enzyme inhibition in rat myocardial infarction. Circ
Res. 1988;62:641650.
139. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol. 1993;25:13691380.[Medline] [Order article via Infotrieve]
140.
Pinto YM, de Smet BG, van Gilst WH, Scholtens E,
Monnink S, de Graeff PA, Wesseling H. Selective and time related
activation of the cardiac renin-angiotensin system after
experimental heart failure: relation to ventricular
function and morphology. Cardiovasc Res. 1993;27:19331938.
141.
Hodsman GP, Kohzuki M, Howes LG, Sumithran E, Tsunoda
K, Johnston CI. Neurohumoral responses to chronic myocardial infarction
in rats. Circulation. 1988;78:376381.
142.
Falkenhahn M, Franke F, Bohle RM, Zhu YC, Stauss HM,
Bachmann S, Danilov S, Unger T. Cellular distribution of
angiotensin-converting enzyme after myocardial infarction.
Hypertension. 1995;25:219226.
143.
Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark
WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte
necrosis. Circ Res. 1989;65:657670.
144. Sun Y, Weber KT. Angiotensin-converting enzyme and wound healing in diverse tissues of the rat. J Lab Clin Med. 1996;127:94101.[Medline] [Order article via Infotrieve]
145. Lefroy DC, Wharton J, Crake T, Knock GA, Rutherford RAD, Suzuki T, Morgan K, Polak JM, Poole-Wilson PA. Regional changes in angiotensin II receptor density after experimental myocardial infarction. J Mol Cell Cardiol. 1996;28:429440.[Medline] [Order article via Infotrieve]
146.
Sechi LA, Griffin CA, Grady EF, Kalinyak JE,
Schambelan M. Characterization of angiotensin II receptor
subtypes in rat heart. Circ Res. 1992;71:14821489.
147.
Regitz-Zagrosek V, Friedel N, Heymann A, Bauer P,
Neuß M, Rolfs A, Steffan C, Hildebrandt A, Hetzer R, Fleck E.
Regulation, chamber localization, and subtype distribution of
angiotensin II receptors in human hearts.
Circulation. 1995;91:14611471.
148. Sun Y, Weber KT. Cells expressing angiotensin II receptors in fibrous tissue of rat heart. Cardiovasc Res. 1996;31:518525.[Medline] [Order article via Infotrieve]
149. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 1995;95:4654.
150. Makino N, Hata T, Sugano M, Dixon IMC, Yanaga T. Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type I receptor in rats. J Mol Cell Cardiol. 1996;28:507517.[Medline] [Order article via Infotrieve]
151. Kimura B, Sumners C, Phillips MI. Changes in skin angiotensin II receptors in rats during wound healing. Biochem Biophys Res Commun. 1992;187:10831090.[Medline] [Order article via Infotrieve]
152. Phillips MI, Kimura B, Gyurko R. Angiotensin receptor stimulation of transforming growth factor-ß in rat skin and wound healing. In: Saavedra JM, Pieter BMWM, eds. Angiotensin Receptors. New York, NY: Plenum Press; 1994:377396.
153. Viswanathan M, Saavedra JM. Expression of angiotensin II AT2 receptors in the rat skin during experimental wound healing. Peptides. 1992;13:783786.[Medline] [Order article via Infotrieve]
154.
Schunkert H, Ingelfinger JR, Hirsch AT, Pinto Y, Remme
WJ, Jacob H, Dzau VJ. Feedback regulation of angiotensin
converting enzyme activity and mRNA levels by angiotensin
II. Circ Res. 1993;72:312318.
155.
Allen RKA, Chai SY, Dunbar MS, Mendelsohn FAO.
In vitro autoradiographic localization of
angiotensin-converting enzyme in sarcoid lymph nodes.
Chest. 1986;90:315320.
156.
Wickline SA, Verdonk ED, Wong AK, Shepard RK, Miller
JG. Structural remodeling of human myocardial tissue after infarction:
quantification with ultrasonic backscatter. Circulation. 1992;85:259268.
157. Campbell DJ, Habener JF. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology.. 1987;121:16161626.
158.
Cassis LA, Lynch KR, Peach MJ. Localization of
angiotensinogen messenger RNA in rat aorta. Circ
Res. 1988;62:12591262.
159.
Sawa H, Tokuchi F, Mochizuki N, Endo Y, Furuta Y,
Shinohara T, Takada A, Kawaguchi H, Yasuda H, Nagashima K. Expression
of the angiotensinogen gene and localization of its protein
in the human heart. Circulation. 1992;86:138146.
160.
Dostal DE, Rothblum KN, Chernin MI, Cooper GR, Baker
KM. Intracardiac detection of angiotensinogen and renin: a
localized renin-angiotensin system in neonatal rat heart.
Am J Physiol. 1992;263:C838C850.
161.
Dostal DE, Rothblum KN, Conrad KM, Cooper GR, Baker
KM. Detection of angiotensin I and II in cultured rat
cardiac myocytes and fibroblasts. Am J Physiol. 1992;263:C851C863.
162.
von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH.
Renin is not synthesized by cardiac and extrarenal vascular tissues: a
review of experimental evidence. Circulation. 1994;89:458470.
163.
Danser AHJ, Koning MMG, Admiraal PJJ, Sassen LMA,
Derkx FHM, Verdouw PD, Schalekamp MADH. Production of
angiotensins I and II at tissue sites in intact pigs.
Am J Physiol. 1992;263:H429H437.
164.
Danser AHJ, Koning MMG, Admiraal PJJ, Derkx FHM,
Verdouw PD, Schalekamp MADH. Metabolism of
angiotensin I by different tissues in the intact animal.
Am J Physiol. 1992;263:H418H428.
165.
Danser AHJ, van Katz JP, Admiraal PJJ, Derkx FHM,
Lamers JMJ, Verdouw PD, Saxena PR, Schalekamp MADH. Cardiac renin and
angiotensins: uptake from plasma versus in situ synthesis.
Hypertension. 1994;24:3748.
166.
Campbell DJ, Kladis A, Duncan AM. Nephrectomy,
converting enzyme inhibition, and angiotensin peptides.
Hypertension. 1993;22:513522.
167. Wintroub BU, Klickstein LB, Dzau VJ, Watt KWK. Granulocyte-angiotensin system: identification of angiotensinogen as the plasma protein substrate of leukocyte cathepsin G. Biochemistry. 1984;23:227232.[Medline] [Order article via Infotrieve]
168. Katwa LC, Campbell SE, Tyagi SC, Lee SJ, Cicila GT, Weber KT. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol. 1997;29:13751386.[Medline] [Order article via Infotrieve]
169.
Passier RCJJ, Smits JFM, Verluyten MJA, Studer R,
Drexler H, Daemen MJAP. Activation of
angiotensin-converting enzyme expression in infarct zone
following myocardial infarction. Am J Physiol. 1995;269:H1268H1276.
170.
Iwai N, Inagami T, Ohmichi N, Kinoshita M. Renin is
expressed in rat macrophage/monocyte cells.
Hypertension. 1996;27:399403.
171.
Zhang X, Dostal DE, Reiss K, Cheng W, Kajstura J, Li
P, Huang H, Sonnenblick EH, Meggs LG, Baker LM, Anversa P.
Identification and activation of autocrine
renin-angiotensin system in adult ventricular
myocytes. Am J Physiol. 1995;269:H1791H1802.
172.
Keeley FW, Elmoselhi A, Leenen FHH. Enalapril
suppresses normal accumulation of elastin and collagen in
cardiovascular tissues of growing rats. Am J
Physiol. 1992;262:H1013H1021.
173.
Albaladejo P, Bouaziz H, Duriez M, Gohlke P, Levy BI,
Safar ME, Benetos A. Angiotensin converting enzyme
inhibition prevents the increase in aortic collagen in rats.
Hypertension. 1994;23:7482.
174.
Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE. Effect
of enalapril on ventricular remodeling and function during
healing after anterior myocardial infarction in the dog.
Circulation. 1995;91:802812.
175. Jugdutt BI, Schwarz-Michorowski BL, Khan MI. Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. J Am Coll Cardiol. 1992;19:713721.[Abstract]
176. Jugdutt BI. Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model. J Am Coll Cardiol. 1995;25:17181725.[Abstract]
177.
Needleman P, Marshall GR, Sobel BE. Hormone
interactions in the isolated rabbit heart: synthesis and
coronary vasomotor effects of prostaglandins,
angiotensin, and bradykinin. Circ Res. 1975;37:802808.
178. Frimm C de C, Sun Y, Weber KT. Wound healing following myocardial infarction in the rat: role for bradykinin and prostaglandins. J Mol Cell Cardiol. 1996;28:12791285.[Medline] [Order article via Infotrieve]
179. Frimm C de C, Sun Y, Weber KT. Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med. 1997;129:439446.[Medline] [Order article via Infotrieve]
180. Makino N, Matsui H, Masutomo K, Hata T, Yanaga T. Effect of angiotensin converting enzyme inhibitor on regression in cardiac hypertrophy. Mol Cell Biochem. 1993;119:2328.[Medline] [Order article via Infotrieve]
181. Bélichard P, Savard P, Cardinal R, Nadeau R, Gosselin H, Paradis P, Rouleau JL. Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. J Am Coll Cardiol. 1994;23:505513.[Abstract]
182. Farivar RS, Crawford DC, Chobanian AV, Brecher P. Effect of angiotensin II blockade on the fibroproliferative response to phenylephrine in the rat heart. Hypertension. 1995;25(pt 2):II-809-II-813.
183. Pimentel JL Jr, Sundell CL, Wang S, Kopp JB, Montero A, Martínez-Maldonado M. Role of angiotensin II in the expression and regulation of transforming growth factor-ß in obstructive nephropathy. Kidney Int. 1995;48:12331246.[Medline] [Order article via Infotrieve]
184. Morrissey JJ, Ishidoya S, McCracken R, Klahr S. The effect of ACE inhibitors on the expression of matrix genes and the role of p53 and p21 (WAF1) in experimental renal fibrosis. Kidney Int. 1996;49(suppl 54):S83S87.
185. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int. 1995;47:12851294.[Medline] [Order article via Infotrieve]
186. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int. 1994;45:16371647.[Medline] [Order article via Infotrieve]
187. Ishidoya S, Morrissey J, McCracken R, Klahr S. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int. 1996;49:11101119.[Medline] [Order article via Infotrieve]
188. Yanagisawa H, Morrissey J, Morrison AR, Klahr S. Eicosanoid production by isolated glomeruli of rats with unilateral ureteral obstruction. Kidney Int. 1990;37:15281535.[Medline] [Order article via Infotrieve]
189. Diamond JR, Anderson S. Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Am J Pathol. 1990;137:13231332.[Abstract]
190. Lafayette RA, Mayer G, Meyer TW. The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. J Am Soc Nephrol. 1993;3:18921899.[Abstract]
191. Cohen EP, Moulder JE, Fish BL, Hill P. Prophylaxis of experimental bone marrow transplant nephropathy. J Lab Clin Med. 1994;124:371380.[Medline] [Order article via Infotrieve]
192. Tanaka R, Sugihara K, Tatematsu A, Fogo A. Internephron heterogeneity of growth factors and sclerosis: modulation of platelet-derived growth factor by angiotensin II. Kidney Int. 1995;47:131139.[Medline] [Order article via Infotrieve]
193. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int. 1991;40:195202.[Medline] [Order article via Infotrieve]
194. Shibouta Y, Chatani F, Ishimura Y, Sanada T, Ohta M, Inada Y, Nishikawa K. TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Kidney Int. 1996;49(suppl 55):S115S118.
195. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:19932000.
196. Juncos LI, Carrasco Dueñas S, Cornejo JC, Broglia CA, Cejas H. Long-term enalapril and hydrochlorothiazide in radiation nephritis. Nephron. 1993;64:249255.[Medline] [Order article via Infotrieve]
197. Nakamura T, Honma H, Ikeda Y, Kuroyanagi R, Takano H, Obata J, Sato T, Kimura H, Yoshida Y, Tamura K. Renal protective effects of angiotensin II receptor I antagonist CV-11974 in spontaneously hypertensive stroke-prone rats (SHR-sp). Blood Press. 1994;3(suppl 5):6166.
198. Nakamura T, Obata J, Kuroyanagi R, Kimura H, Ikeda Y, Takano H, Naito A, Sato T, Yoshida Y. Involvement of angiotensin II in glomerulosclerosis of stroke-prone spontaneously hypertensive rats. Kidney Int. 1996;49(suppl 55):S109S112.
199. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int. 1994;46:13461358.[Medline] [Order article via Infotrieve]
200.
Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura
K, Inada Y, Ishimura Y, Chatani F, Iwao H. Angiotensin II
type I receptor antagonist inhibits the gene expression of
transforming growth factor-ß1 and extracellular matrix in
cardiac and vascular tissues of hypertensive rats. J
Pharmacol Exp Ther. 1995;273:509515.
201. Ward WF, Molteni A, Ts'ao C. Radiation-induced endothelial dysfunction and fibrosis in rat lung: modification by the angiotensin converting enzyme inhibitor CL242817. Radiat Res. 1989;117:342350.[Medline] [Order article via Infotrieve]
202. Ward WF, Molteni A, Ts'ao C, Kim YT, Hinz JM. Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys. 1992;22:623625.[Medline] [Order article via Infotrieve]
203. Ward WF, Molteni A, Ts'ao C-H, Hinz JM. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int J Radiat Oncol Biol Phys. 1990;19:14051409.[Medline] [Order article via Infotrieve]
204. Molteni A, Ward WF, Ts'ao C, Soliday NH, Dunnes M. Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine. Proc Soc Exp Biol Med. 1985;180:112120.[Medline] [Order article via Infotrieve]
205. Sun Y, Ramires FJA, Zhou G, Ganjam VK, Weber KT. Fibrous tissue and angiotensin II. J Mol Cell Cardiol. 1997;29:20012012.[Medline] [Order article via Infotrieve]
206. Weber KT. Fibrosis: a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol. 1997;17:467491.[Medline] [Order article via Infotrieve]
207.
Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann
WH. Identification of functional angiotensin II receptors
on rat cardiac fibroblasts. Circulation. 1993;88:28492861.
208. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809820.[Medline] [Order article via Infotrieve]
209. Zhou G, Kandala JC, Tyagi SC, Katwa LC, Weber KT. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem. 1996;154:171178.[Medline] [Order article via Infotrieve]
210. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-ß1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol. 1995;27:23472357.[Medline] [Order article via Infotrieve]
211.
Tufro-McReddie A, Chevalier RL, Everett AD, Gomez RA.
Decreased perfusion pressure modulates renin and ANG II type 1 receptor
gene expression in the rat kidney. Am J Physiol. 1993;264:R696R702.
212.
Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO,
Schunkert H, Diamant D, Tang SS. Distribution and function of cardiac
angiotensin AT1- and
AT2-receptor subtypes in hypertrophied rat
hearts. Am J Physiol. 1994;267:H844H852.
213.
Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT.
Remodeling of the rat right and left ventricle in experimental
hypertension. Circ Res. 1990;67:13551364.
214.
Chapman D, Weber KT, Eghbali M. Regulation of
fibrillar collagen types I and III and basement membrane type IV
collagen gene expression in pressure overloaded rat
myocardium. Circ Res. 1990;67:787794.
215. Willems IEMG, Havenith MG, Smits JFM, Daemen MJAP. Structural alterations in heart valves during left ventricular pressure overload in the rat. Lab Invest. 1994;71:127133.[Medline] [Order article via Infotrieve]
216. Goldblatt H. Experimental hypertension induced by renal ischemia (Harvey Lecture). Bull N Y Acad Med. 1938;14:523553.[Medline] [Order article via Infotrieve]
217.
Selye H. The general adaptation syndrome and the
diseases of adaptation. J Clin Endocrinol. 1946;6:117230.
218. Hall CE, Hall O. Hypertension and hypersalimentation, I: aldosterone hypertension. Lab Invest. 1965;14:285294.[Medline] [Order article via Infotrieve]
219. Nicoletti A, Mandet C, Challah M, Bariéty J, Michel J-B. Mediators of perivascular inflammation in the left ventricle of renovascular hypertensive rats. Cardiovasc Res. 1996;31:585595.[Medline] [Order article via Infotrieve]
220. Jalil JE, Janicki JS, Pick R, Weber KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J Hypertens. 1991;4:5155.[Medline] [Order article via Infotrieve]
221.
Nicoletti A, Heudes D, Hinglais N, Appay M-D, Philippe
M, Sassy-Prigent C, Bariety J, Michel J-B. Left ventricular
fibrosis in renovascular hypertensive rats: effect of losartan
and spironolactone. Hypertension. 1995;26:101111.
222.
Regan CP, Anderson PG, Bishop SP, Berecek KH.
Captopril prevents vascular and fibrotic changes but not cardiac
hypertrophy in aortic-banded rats. Am J
Physiol. 1996;271:H906H913.
223. Linz W, Schaper J, Wiemer G, Albus U, Schölkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol. 1992;107:970975.[Medline] [Order article via Infotrieve]
224.
Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl
P, Floege J, Schwartz SM. Renal injury from angiotensin
II-mediated hypertension. Hypertension. 1992;19:464474.
225.
Crawford DC, Chobanian AV, Brecher P.
Angiotensin II induces fibronectin expression associated
with cardiac fibrosis in the rat. Circ Res. 1994;74:727739.
226.
Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao
H. Angiotensin II induces cardiac phenotypic modulation and
remodeling in vivo in rats. Hypertension. 1995;25:12521259.
227. Weber KT, Sun Y, Guarda E. Nonclassic actions of angiotensin II and aldosterone in nonclassic target tissue (the heart): relevance to hypertensive heart disease. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995;2:22032223.
228.
Weber KT. Hormones and fibrosis: a case for lost
reciprocal regulation. News Physiol Sci. 1994;9:123128.
229. Brenner DA, Rippe RA, Rhodes K, Trotter JF, Breindl M. Fibrogenesis and type I collagen gene regulation. J Lab Clin Med. 1994;124:755760.[Medline] [Order article via Infotrieve]
230. Appleton I, Tomlinson A, Chander CL, Willoughby DA. Effect of endothelin-1 on croton oil-induced granulation tissue in the rat: a pharmacologic and immunohistochemical study. Lab Invest. 1992;67:703710.[Medline] [Order article via Infotrieve]
231. Zeballos GA, An SJ, Wu JM. Endothelin-1 secretion by human fibroblasts in culture: effects of cell density and IFN-ß. Biochem Int. 1991;25:845852.[Medline] [Order article via Infotrieve]
232.
Firth JD, Schricker K, Ratcliffe PJ, Kurtz A.
Expression of endothelins 1 and 3 in the rat kidney. Am J
Physiol. 1995;269:F522F528.
233.
Ikeda M, Kohno M, Takeda T. Endothelin
production in cultured mesangial cells of
spontaneously hypertensive rats. Hypertension. 1995;25:11961201.
234.
Bakris GL, Re RN. Endothelin modulates
angiotensin II-induced mitogenesis of human
mesangial cells. Am J Physiol. 1993;264:F937F942.
235.
Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT.
Effects of endothelins on collagen turnover in cardiac fibroblasts.
Cardiovasc Res. 1993;27:21302134.
236.
Katwa LC, Guarda E, Weber KT. Endothelin receptors in
cultured adult rat cardiac fibroblasts. Cardiovasc Res. 1993;27:21252129.
237.
Schrey MP, Patel KV, Tezapsidis N. Bombesin and
glucocorticoids stimulate human breast cancer cells to produce
endothelin, a paracrine mitogen for breast stromal cells. Cancer
Res. 1992;52:17861790.
238. Karam H, Heudes D, Hess P, Gonzales MF, Loffler BM, Clozel M, Clozel JP. Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc Res. 1996;31:287295.[Medline] [Order article via Infotrieve]
239. Benigni A, Zoja C, Corna D, Orisio S, Longaretti K, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1994;46:696702.[Medline] [Order article via Infotrieve]
240. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995;9:13191330.[Abstract]
241. Lyons CR. The role of nitric oxide in inflammation. Adv Immunol. 1995;60:323371.[Medline] [Order article via Infotrieve]
242.
Nathan C, Xie Q. Regulation of biosynthesis of nitric
oxide. J Biol Chem. 1994;269:1372513728.
243. Takagi K, Isobe Y, Yasukawa K, Okouchi E, Suketa Y. Nitric oxide blocks the cell cycle of mouse macrophage-like cells in the G2+M phase. FEBS Lett. 1994;340:159162.[Medline] [Order article via Infotrieve]
244. Sigusch HH, Campbell SE, Weber KT. Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. Cardiovasc Res. 1996;31:546554.[Medline] [Order article via Infotrieve]
245. Hou J, Kato H, Cohen RA, Chobanian AV, Brecher P. Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase. J Clin Invest. 1996;96:24692477.
246.
Numaguchi K, Egashira K, Takemoto M, Kadokami T,
Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide
synthesis causes coronary microvascular remodeling in rats.
Hypertension. 1995;26:957962.
247. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 1997;99:278287.[Medline] [Order article via Infotrieve]
248. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:146.[Medline] [Order article via Infotrieve]
249. Evers AS, Murphree S, Saffitz JE, Jakschik BA, Needleman P. Effects of endogenously produced leukotrienes, thromboxane, and prostaglandins on coronary vascular resistance in rabbit myocardial infarction. J Clin Invest. 1985;75:992999.
250. Herman AG, Claeys M, Moncada S, Vane JR. Biosynthesis of prostacyclin (PGI2) and 12L-hydroxy-5,8,10,14-eicosatetraenoic acid (HETE) by pericardium, pleura, peritoneum and aorta of the rabbit. Prostaglandins. 1979;18:439452.[Medline] [Order article via Infotrieve]
251. Satoh K, Prescott SM. Culture of mesothelial cells from bovine pericardium and characterization of their arachidonate metabolism. Biochim Biophys Acta. 1980;930:283296.
252.
Bareis DL, Manganiello VC, Hirata F, Vaughan M,
Axelrod J. Bradykinin stimulates phospholipid methylation, calcium
influx, prostaglandin formation, and cAMP accumulation in
human fibroblasts. Proc Natl Acad Sci U S A. 1983;80:25142518.
253. Korn JH. Fibroblast prostaglandin E2 synthesis: persistence of an abnormal phenotype after short-term exposure to mononuclear cell products. J Clin Invest. 1983;71:12401246.
254.
Weber DR, Stroud ED, Prescott SM.
Arachidonate metabolism in cultured fibroblasts
derived from normal and infarcted canine heart. Circ Res. 1989;65:671683.
255. Lindpaintner K, Lu W, Niedermajer J, Schieffer B, Just H, Ganten D, Drexler H. Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat. J Mol Cell Cardiol. 1993;25:133143.[Medline] [Order article via Infotrieve]
256.
McCluskey ER, Corr PB, Lee BI, Saffitz JE, Needleman
P. The arachinodic acid metabolic capacity of canine
myocardium is increased during healing of acute myocardial
infarction. Circ Res. 1982;51:743750.
257.
Vane JR, Mitchell JA, Appleton I, Tomlinson A,
Bishop-Bailey D, Croxtall J, Willoughby DA. Inducible isoforms of
cyclooxygenase and nitric-oxide synthase in
inflammation. Proc Natl Acad Sci U S A. 1994;91:20462050.
258.
Stuehr DJ, Nathan CF. Nitric oxide: a
macrophage product responsible for cytostasis and
respiratory inhibition in tumor target cells. J Exp Med. 1989;169:15431555.
259. Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol. 1993;150:50805085.[Abstract]
260. Silverstein E, Friedland J, Vuletin JC. Marked elevation of serum angiotensin-converting enzyme and hepatic fibrosis containing long-spacing collagen fibrils in type 2 acute neuronopathic Gaucher's disease. Am J Clin Pathol. 1978;69:467471.[Medline] [Order article via Infotrieve]
261. Chua CC, Hamdy RC, Chua BHL. Angiotensin II induces TIMP-1 production in rat heart endothelial cells. Biochim Biophys Acta. 1996;1311:175180.[Medline] [Order article via Infotrieve]
262.
Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda
R, Yamamoto H. Vascular aldosterone: biosynthesis and a
link to angiotensin II-induced hypertrophy of
vascular smooth muscle cells. J Biol Chem. 1994;269:2431624320.
263. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh F-Y, Takeda R. Synthesis of corticosterone in the vascular wall. Endocrinology. 1994;135:22832286.[Abstract]
264.
Klauber N, Browne F, Anand-Apte B, D'Amato RJ. New
activity of spironolactone: inhibition of angiogenesis in vitro and in
vivo. Circulation. 1996;94:25662571.
265. Guntaka RV, Kovacs A, Kandala JC, Weber KT. Regulation of fibrillar collagen gene expression. In: Weber KT, ed. Wound Healing in Cardiovascular Disease. Armonk, NY: Futura; 1995:281294.
266. Irle C, Kocher O, Gabbiani G. Contractility of myofibroblasts during experimental liver cirrhosis. J Submicrosc Cytol. 1980;12:209217.
267. Evans JN, Kelley J, Low RB, Adler KB. Increased contractility of isolated lung parenchyma in an animal model of pulmonary fibrosis induced by bleomycin. Am Rev Respir Dis. 1982;125:8994.[Medline] [Order article via Infotrieve]
268. De Mey JGR, Fazzi GE. A smooth muscle-like component in rat myocardial infarcts. Hypertension. 1996;28:696. Abstract.
269.
Kessler KM. Heart failure with normal systolic
function: update of prevalence, differential diagnosis, prognosis, and
therapy. Arch Intern Med. 1988;148:21092111.
270. Pearlman ES, Weber KT, Janicki JS, Pietra G, Fishman AP. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982;46:158164.[Medline] [Order article via Infotrieve]
271. Huysman JAN, Vliegen HW, Van der Laarse A, Eulderink F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract. 1989;184:577581.[Medline] [Order article via Infotrieve]
272.
Haber HL, Powers ER, Gimple LW, Wu CC, Subbiah K,
Johnson WH, Feldman MD. Intracoronary
angiotensin-converting enzyme inhibition improves
diastolic function in patients with hypertensive left
ventricular hypertrophy.
Circulation. 1994;89:26162625.
273.
Friedrich SP, Lorell BH, Rousseau MF, Hayashida W,
Hess OM, Douglas PS, Gordon S, Keighley CS, Benedict C, Krayenbuehl HP,
Grossman W, Pouleur H. Intracardiac angiotensin-converting
enzyme inhibition improves diastolic function in patients
with left ventricular hypertrophy due to aortic
stenosis. Circulation. 1994;90:27612771.
274. Krayenbuehl HP, Hess OM, Schneider J, Turina M. Physiologic or pathologic hypertrophy. Eur Heart J. 1983;4:2934.
275.
Hess OM, Ritter M, Schneider J, Grimm J, Turina
M, Krayenbuehl HP. Diastolic stiffness and myocardial
structure in aortic valve disease before and after valve replacement.
Circulation. 1984;69:855865.
276. Villari B, Campbell SE, Hess OM, Mall G, Weber KT, Krayenbuehl HP. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol. 1993;22:14771484.[Abstract]
277. Rousseau MF, Gurnè O, van Eyll C, Benedict CR, Pouleur H. Effects of benazeprilat on left ventricular systolic and diastolic function and neurohormonal status in patients with ischemic heart disease. Circulation. 1990;81(suppl III):III-123-III-129
This article has been cited by other articles:
![]() |
N. Hedhli and C. Depre Proteasome inhibitors and cardiac cell growth Cardiovasc Res, August 7, 2009; (2009) cvp226v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xie, A. Garfinkel, J. N. Weiss, and Z. Qu Cardiac alternans induced by fibroblast-myocyte coupling: mechanistic insights from computational models Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H775 - H784. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matsushima, S. Kinugawa, T. Yokota, N. Inoue, Y. Ohta, S. Hamaguchi, and H. Tsutsui Increased myocardial NAD(P)H oxidase-derived superoxide causes the exacerbation of postinfarct heart failure in type 2 diabetes Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H409 - H416. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Pavlopoulos and P. Nihoyannopoulos Pulse pressure/stroke volume: a surrogate index of arterial stiffness and the relation to segmental relaxation and longitudinal systolic deformation in hypertensive disease Eur J Echocardiogr, June 1, 2009; 10(4): 519 - 526. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Villarreal, S. A. Epperson, I. Ramirez-Sanchez, K. G. Yamazaki, and L. L. Brunton Regulation of cardiac fibroblast collagen synthesis by adenosine: roles for Epac and PI3K Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1178 - C1184. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun Myocardial repair/remodelling following infarction: roles of local factors Cardiovasc Res, February 15, 2009; 81(3): 482 - 490. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W.M. van den Borne, S. Isobe, J. W. Verjans, A. Petrov, D. Lovhaug, P. Li, H. R. Zandbergen, Y. Ni, P. Frederik, J. Zhou, et al. Molecular Imaging of Interstitial Alterations in Remodeling Myocardium After Myocardial Infarction J. Am. Coll. Cardiol., December 9, 2008; 52(24): 2017 - 2028. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Greenberg An ACE in the Hole: Alternative Pathways of the Renin Angiotensin System and Their Potential Role in Cardiac Remodeling J. Am. Coll. Cardiol., August 26, 2008; 52(9): 755 - 757. [Full Text] [PDF] |
||||
![]() |
X. Xu, W. Wan, L. Ji, S. Lao, A. S. Powers, W. Zhao, J. M. Erikson, and J. Q. Zhang Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats Cardiovasc Res, June 1, 2008; 78(3): 523 - 532. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W.H. Verjans, D. Lovhaug, N. Narula, A. D. Petrov, B. Indrevoll, E. Bjurgert, T. B. Krasieva, L. B. Petersen, G. M. Kindberg, M. Solbakken, et al. Noninvasive imaging of angiotensin receptors after myocardial infarction. J. Am. Coll. Cardiol. Img., May 1, 2008; 1(3): 354 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Hill and E. N. Olson Cardiac Plasticity N. Engl. J. Med., March 27, 2008; 358(13): 1370 - 1380. [Full Text] [PDF] |
||||
![]() |
C. F.M.Z. Clemente, T. F. Tornatore, T. H. Theizen, A. C. Deckmann, T. C. Pereira, I. Lopes-Cendes, J. R. M. Souza, and K. G. Franchini Targeting Focal Adhesion Kinase With Small Interfering RNA Prevents and Reverses Load-Induced Cardiac Hypertrophy in Mice Circ. Res., December 7, 2007; 101(12): 1339 - 1348. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Swaney, H. H. Patel, U. Yokoyama, N. C. Lai, M. Spellman, P. A. Insel, and D. M. Roth Adenylyl cyclase activity and function are decreased in rat cardiac fibroblasts after myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3216 - H3220. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Vellaichamy, D. Zhao, N. Somanna, and K. N. Pandey Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy Physiol Genomics, October 19, 2007; 31(2): 193 - 202. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. I. Dedkov, W. Zheng, L. P. Christensen, R. M. Weiss, F. Mahlberg-Gaudin, and R. J. Tomanek Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H590 - H598. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Radauceanu, F. Moulin, W. Djaballah, P. Y. Marie, F. Alla, B. Dousset, J. M. Virion, J. Capiaumont, G. Karcher, E. Aliot, et al. Residual stress ischaemia is associated with blood markers of myocardial structural remodelling Eur J Heart Fail, April 1, 2007; 9(4): 370 - 376. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wakeno, T. Minamino, O. Seguchi, H. Okazaki, O. Tsukamoto, K.-i. Okada, A. Hirata, M. Fujita, H. Asanuma, J. Kim, et al. Long-Term Stimulation of Adenosine A2b Receptors Begun After Myocardial Infarction Prevents Cardiac Remodeling in Rats Circulation, October 31, 2006; 114(18): 1923 - 1932. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Shirwany and K. T. Weber Extracellular Matrix Remodeling in Hypertensive Heart Disease J. Am. Coll. Cardiol., July 4, 2006; 48(1): 97 - 98. [Full Text] [PDF] |
||||
![]() |
S. Johar, A. C. Cave, A. Narayanapanicker, D. J. Grieve, and A. M. Shah Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase FASEB J, July 1, 2006; 20(9): 1546 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Lindsey, G. P. Escobar, R. Mukherjee, D. K. Goshorn, N. J. Sheats, J. A. Bruce, I. M. Mains, J. K. Hendrick, K. W. Hewett, R. G. Gourdie, et al. Matrix Metalloproteinase-7 Affects Connexin-43 Levels, Electrical Conduction, and Survival After Myocardial Infarction Circulation, June 27, 2006; 113(25): 2919 - 2928. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Helske, S. Syvaranta, M. Kupari, J. Lappalainen, M. Laine, J. Lommi, H. Turto, M. Mayranpaa, K. Werkkala, P. T. Kovanen, et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves Eur. Heart J., June 2, 2006; 27(12): 1495 - 1504. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Grieve, J. A. Byrne, A. Siva, J. Layland, S. Johar, A. C. Cave, and A. M. Shah Involvement of the Nicotinamide Adenosine Dinucleotide Phosphate Oxidase Isoform Nox2 in Cardiac Contractile Dysfunction Occurring in Response to Pressure Overload J. Am. Coll. Cardiol., February 21, 2006; 47(4): 817 - 826. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Vanhoutte, M. Schellings, Y. Pinto, and S. Heymans Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window Cardiovasc Res, February 15, 2006; 69(3): 604 - 613. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Dean, L. C. Balding, R. Candido, W. C. Burns, Z. Cao, S. M. Twigg, and L. M. Burrell Connective Tissue Growth Factor and Cardiac Fibrosis after Myocardial Infarction J. Histochem. Cytochem., October 1, 2005; 53(10): 1245 - 1256. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A Voors, P. P. van Geel, H. Buikema, M. Oosterga, D. J van Veldhuisen, and W. H van Gilst High Angiotensin II Responsiveness is Associated with Decreased Endothelium-Dependent Relaxation in Human Arteries Journal of Renin-Angiotensin-Aldosterone System, September 1, 2005; 6(3): 145 - 150. [Abstract] [PDF] |
||||
![]() |
K. Chen, J. Chen, Y. Liu, J. Xie, D. Li, T. Sawamura, P. L. Hermonat, and J. L. Mehta Adhesion Molecule Expression in Fibroblasts: Alteration in Fibroblast Biology After Transfection With LOX-1 Plasmids Hypertension, September 1, 2005; 46(3): 622 - 627. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Berenji, M. H. Drazner, B. A. Rothermel, and J. A. Hill Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H8 - H16. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Stawowy, C. Margeta, F. Blaschke, C. Lindschau, C. Spencer-Hansch, M. Leitges, G. Biagini, E. Fleck, and K. Graf Protein kinase C epsilon mediates angiotensin II-induced activation of {beta}1-integrins in cardiac fibroblasts Cardiovasc Res, July 1, 2005; 67(1): 50 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fraccarollo, P. Galuppo, I. Schmidt, G. Ertl, and J. Bauersachs Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction Cardiovasc Res, July 1, 2005; 67(1): 97 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Mann and M. R. Bristow Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond Circulation, May 31, 2005; 111(21): 2837 - 2849. [Full Text] [PDF] |
||||
![]() |
Z. A. Abassi, A. Yahia, S. Zeid, T. Karram, E. Golomb, J. Winaver, and A. Hoffman Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H722 - H728. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chen, J. L. Mehta, D. Li, L. Joseph, and J. Joseph Transforming Growth Factor {beta} Receptor Endoglin Is Expressed in Cardiac Fibroblasts and Modulates Profibrogenic Actions of Angiotensin II Circ. Res., December 10, 2004; 95(12): 1167 - 1173. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Helske, K. A. Lindstedt, M. Laine, M. Mayranpaa, K. Werkkala, J. Lommi, H. Turto, M. Kupari, and P. T. Kovanen Induction of local angiotensin II-producing systems in stenotic aortic valves J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1859 - 1866. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Maekawa, T. Anzai, T. Yoshikawa, Y. Sugano, K. Mahara, T. Kohno, T. Takahashi, and S. Ogawa Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1510 - 1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Akar, D. D. Spragg, R. S. Tunin, D. A. Kass, and G. F. Tomaselli Mechanisms Underlying Conduction Slowing and Arrhythmogenesis in Nonischemic Dilated Cardiomyopathy Circ. Res., October 1, 2004; 95(7): 717 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Querejeta, B. Lopez, A. Gonzalez, E. Sanchez, M. Larman, J. L. Martinez Ubago, and J. Diez Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis Circulation, September 7, 2004; 110(10): 1263 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yamamoto, Y. Takahashi, T. Mano, Y. Sakata, N. Nishikawa, J. Yoshida, Y. Oishi, M. Hori, T. Miwa, S. Inoue, et al. N-Methylethanolamine attenuates cardiac fibrosis and improves diastolic function: inhibition of phospholipase D as a possible mechanism Eur. Heart J., July 2, 2004; 25(14): 1221 - 1229. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lopez, R. Querejeta, A. Gonzalez, E. Sanchez, M. Larman, and J. Diez Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2028 - 2035. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Jin, S. Takai, M. Sakaguchi, Y. Okamoto, M. Muramatsu, and M. Miyazaki An Antiarrhythmic Effect of a Chymase Inhibitor after Myocardial Infarction J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 490 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yoshida, K. Yamamoto, T. Mano, Y. Sakata, N. Nishikawa, M. Nishio, T. Ohtani, T. Miwa, M. Hori, and T. Masuyama AT1 Receptor Blocker Added to ACE Inhibitor Provides Benefits at Advanced Stage of Hypertensive Diastolic Heart Failure Hypertension, March 1, 2004; 43(3): 686 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, I. Kishimoto, Y. Saito, M. Harada, K. Kuwahara, T. Izumi, I. Hamanaka, N. Takahashi, R. Kawakami, K. Tanimoto, et al. Androgen Contributes to Gender-Related Cardiac Hypertrophy and Fibrosis in Mice Lacking the Gene Encoding Guanylyl Cyclase-A Endocrinology, February 1, 2004; 145(2): 951 - 958. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chandrashekhar, S. Sen, R. Anway, A. Shuros, and I. Anand Long-Term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction J. Am. Coll. Cardiol., January 21, 2004; 43(2): 295 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tiede, K. Stoter, C. Petrik, W.-B. Chen, H. Ungefroren, M.-L. Kruse, M. Stoll, T. Unger, and J. W Fischer Angiotensin II AT1-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGF{beta} in vitro Cardiovasc Res, December 1, 2003; 60(3): 538 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Guo and L. Piacentini Type I Collagen-induced MMP-2 Activation Coincides with Up-regulation of Membrane Type 1-Matrix Metalloproteinase and TIMP-2 in Cardiac Fibroblasts J. Biol. Chem., November 21, 2003; 278(47): 46699 - 46708. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fraccarollo, P. Galuppo, S. Hildemann, M. Christ, G. Ertl, and J. Bauersachs Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1666 - 1673. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Solomon and M. A. Pfeffer Aldosterone antagonism and myocardial infarction: From animals to man and back J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1674 - 1676. [Full Text] [PDF] |
||||
![]() |
D. Jin, S. Takai, M. Yamada, M. Sakaguchi, K. Kamoshita, K. Ishida, Y. Sukenaga, and M. Miyazaki Impact of chymase inhibitor on cardiac function and survival after myocardial infarction Cardiovasc Res, November 1, 2003; 60(2): 413 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tsuda, E. Gao, L. Evangelisti, D. Markova, X. Ma, and M.-L. Chu Post-ischemic myocardial fibrosis occurs independent of hemodynamic changes Cardiovasc Res, October 1, 2003; 59(4): 926 - 933. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. I. Jugdutt Ventricular Remodeling After Infarction and the Extracellular Collagen Matrix: When Is Enough Enough? Circulation, September 16, 2003; 108(11): 1395 - 1403. [Full Text] [PDF] |
||||
![]() |
A. Gonzalez, M. A Fortuno, R. Querejeta, S. Ravassa, B. Lopez, N. Lopez, and J. Diez Cardiomyocyte apoptosis in hypertensive cardiomyopathy Cardiovasc Res, September 1, 2003; 59(3): 549 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Lindsey, J. Yoshioka, C. MacGillivray, S. Muangman, J. Gannon, A. Verghese, M. Aikawa, P. Libby, S. M. Krane, and R. T. Lee Effect of a Cleavage-Resistant Collagen Mutation on Left Ventricular Remodeling Circ. Res., August 8, 2003; 93(3): 238 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shiomi, H. Tsutsui, M. Ikeuchi, H. Matsusaka, S. Hayashidani, N. Suematsu, J. Wen, T. Kubota, and A. Takeshita Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction J. Am. Coll. Cardiol., July 2, 2003; 42(1): 165 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Ostrom, J. E. Naugle, M. Hase, C. Gregorian, J. S. Swaney, P. A. Insel, L. L. Brunton, and J. G. Meszaros Angiotensin II Enhances Adenylyl Cyclase Signaling via Ca2+/Calmodulin: Gq-Gs CROSS-TALK REGULATES COLLAGEN PRODUCTION IN CARDIAC FIBROBLASTS J. Biol. Chem., June 27, 2003; 278(27): 24461 - 24468. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lijnen, V. Petrov, and R. Fagard Transforming growth factor-{beta}1-mediated collagen gel contraction by cardiac fibroblasts Journal of Renin-Angiotensin-Aldosterone System, June 1, 2003; 4(2): 113 - 118. [Abstract] [PDF] |
||||
![]() |
M. St John Sutton, D. Lee, J. L. Rouleau, S. Goldman, T. Plappert, E. Braunwald, and M. A. Pfeffer Left Ventricular Remodeling and Ventricular Arrhythmias After Myocardial Infarction Circulation, May 27, 2003; 107(20): 2577 - 2582. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Fortuno, A. Gonzalez, S. Ravassa, B. Lopez, and J. Diez Clinical implications of apoptosis in hypertensive heart disease Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1495 - H1506. [Full Text] [PDF] |
||||
![]() |
T. Maki, Y. Nasa, K. Tanonaka, M. Takahashi, and S. Takeo Beneficial Effects of Sampatrilat, a Novel Vasopeptidase Inhibitor, on Cardiac Remodeling and Function of Rats with Chronic Heart Failure following Left Coronary Artery Ligation J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 97 - 105. [Abstract] [Full Text] |
||||
![]() |
D. L. Brutsaert Cardiac Endothelial-Myocardial Signaling: Its Role in Cardiac Growth, Contractile Performance, and Rhythmicity Physiol Rev, January 1, 2003; 83(1): 59 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Peng, D. Gurantz, V. Tran, R. T. Cowling, and B. H. Greenberg Tumor Necrosis Factor-{alpha}-Induced AT1 Receptor Upregulation Enhances Angiotensin II-Mediated Cardiac Fibroblast Responses That Favor Fibrosis Circ. Res., December 13, 2002; 91(12): 1119 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Reinhardt, H H Sigusch, J Hensse, S C Tyagi, R Korfer, and H R Figulla Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP Heart, December 1, 2002; 88(5): 525 - 530. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. R. Heyen, E. R. Blasi, K. Nikula, R. Rocha, H. A. Daust, G. Frierdich, J. F. Van Vleet, P. De Ciechi, E. G. McMahon, and A. E. Rudolph Structural, functional, and molecular characterization of the SHHF model of heart failure Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1775 - H1784. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Freshour, S. E. Chase, and K. L. Vikstrom Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1997 - H2003. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Solomon and M. A. Pfeffer Renin-Angiotensin System and Cardiac Rupture After Myocardial Infarction Circulation, October 22, 2002; 106(17): 2167 - 2169. [Full Text] [PDF] |
||||
![]() |
Y. Li, I. Kishimoto, Y. Saito, M. Harada, K. Kuwahara, T. Izumi, N. Takahashi, R. Kawakami, K. Tanimoto, Y. Nakagawa, et al. Guanylyl Cyclase-A Inhibits Angiotensin II Type 1A Receptor-Mediated Cardiac Remodeling, an Endogenous Protective Mechanism in the Heart Circulation, September 24, 2002; 106(13): 1722 - 1728. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Neagoe, M. Kulke, F. del Monte, J. K. Gwathmey, P. P. de Tombe, R. J. Hajjar, and W. A. Linke Titin Isoform Switch in Ischemic Human Heart Disease Circulation, September 10, 2002; 106(11): 1333 - 1341. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G.F Bronzwaer, C. Zeitz, C. A Visser, and W. J Paulus Endomyocardial nitric oxide synthase and the hemodynamic phenotypes of human dilated cardiomyopathy and of athlete's heart Cardiovasc Res, August 1, 2002; 55(2): 270 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fraccarollo, P. Galuppo, J. Bauersachs, and G. Ertl Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling: Presented in part at the 72nd Scientific Session of the American Heart Association, Atlanta, GA, USA, November 7-10, 1999, and published in abstract form (Circulation 1999;100(Suppl. 1):562) Cardiovasc Res, June 1, 2002; 54(3): 559 - 567. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Perry, C.-C. Wei, G. H. Hankes, S. R. Dillon, P. Rynders, R. Mukherjee, F. G. Spinale, and L. J. Dell'Italia Angiotensin II receptor blockade does not improve left ventricular function andremodeling in subacute mitral regurgitation in the dog J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1374 - 1379. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Ferrara, F Mastrorilli, G Pasanisi, S Censi, N D'aiello, A Fucili, M Valgimigli, and R Ferrari Neurohormonal modulation in chronic heart failure Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D3 - D11. [Abstract] [PDF] |
||||
![]() |
D. Fraccarollo, J. Bauersachs, M. Kellner, P. Galuppo, and G. Ertl Cardioprotection by long-term ETA receptor blockade and ACE inhibition in rats with congestive heart failure: mono- versus combination therapy Cardiovasc Res, April 1, 2002; 54(1): 85 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Cowling, D. Gurantz, J. Peng, W. H. Dillmann, and B. H. Greenberg Transcription Factor NF-kappa B Is Necessary for Up-regulation of Type 1 Angiotensin II Receptor mRNA in Rat Cardiac Fibroblasts Treated with Tumor Necrosis Factor-alpha or Interleukin-1beta J. Biol. Chem., February 15, 2002; 277(8): 5719 - 5724. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. LIU, M. SUGA, A. A. MACLEAN, J. A. ST. GEORGE, D. W. SOUZA, and S. KESHAVJEE Soluble Transforming Growth Factor-beta Type III Receptor Gene Transfection Inhibits Fibrous Airway Obliteration in a Rat Model of Bronchiolitis Obliterans Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 419 - 423. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Bendall, A. C. Cave, C. Heymes, N. Gall, and A. M. Shah Pivotal Role of a gp91phox-Containing NADPH Oxidase in Angiotensin II-Induced Cardiac Hypertrophy in Mice Circulation, January 22, 2002; 105(3): 293 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Weber Aldosterone in Congestive Heart Failure N. Engl. J. Med., December 6, 2001; 345(23): 1689 - 1697. [Full Text] [PDF] |
||||
![]() |
F. W. Bowen, S. C. Jones, N. Narula, M. G. St. John Sutton, T. Plappert, L. H. Edmunds Jr, and I. M.C. Dixon Restraining acute infarct expansion decreases collagenase activity in borderzone myocardium Ann. Thorac. Surg., December 1, 2001; 72(6): 1950 - 1956. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Frohlich Local Hemodynamic Changes in Hypertension: Insights for Therapeutic Preservation of Target Organs Hypertension, December 1, 2001; 38(6): 1388 - 1394. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Capomolla, G. Pinna, O. Febo, A. Caporotondi, G. Guazzotti, M. T. La Rovere, M. Gnemmi, A. Mortara, R. Maestri, and F. Cobelli Echo-Doppler mitral flow monitoring: an operative tool to evaluate day-to-day tolerance to and effectiveness of beta-adrenergic blocking agent therapy in patients with chronic heart failure J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1675 - 1684. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Nwogu, D. Geenen, M. Bean, M. C. Brenner, X. Huang, and P. M. Buttrick Inhibition of Collagen Synthesis With Prolyl 4-Hydroxylase Inhibitor Improves Left Ventricular Function and Alters the Pattern of Left Ventricular Dilatation After Myocardial Infarction Circulation, October 30, 2001; 104(18): 2216 - 2221. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bauersachs, P. Galuppo, D. Fraccarollo, M. Christ, and G. Ertl Improvement of Left Ventricular Remodeling and Function by Hydroxymethylglutaryl Coenzyme A Reductase Inhibition With Cerivastatin in Rats With Heart Failure After Myocardial Infarction Circulation, August 28, 2001; 104(9): 982 - 985. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R Kalra, S. D Anker, and A. J.S Coats Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res, August 15, 2001; 51(3): 495 - 509. [Full Text] [PDF] |
||||
![]() |
S. Ichihara, T. Senbonmatsu, E. Price Jr, T. Ichiki, F. A. Gaffney, and T. Inagami Angiotensin II Type 2 Receptor Is Essential for Left Ventricular Hypertrophy and Cardiac Fibrosis in Chronic Angiotensin II-Induced Hypertension Circulation, July 17, 2001; 104(3): 346 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. de Simone, F. Pasanisi, and F. Contaldo Link of Nonhemodynamic Factors to Hemodynamic Determinants of Left Ventricular Hypertrophy Hypertension, July 1, 2001; 38(1): 13 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J Lijnen, V. V Petrov, and R. H Fagard Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors Journal of Renin-Angiotensin-Aldosterone System, June 1, 2001; 2(2): 117 - 122. [Abstract] [PDF] |
||||
![]() |
R. Ferrari Pathophysiological vs biochemical ischaemia: a key to transition from reversible to irreversible damage Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C2 - C10. [Abstract] [PDF] |
||||
![]() |
T. Omland, W. Johnson, M. B. Gordon, and M. A. Creager Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H2248 - H2254. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yoshida, K. Tanonaka, Y. Miyamoto, T. Abe, M. Takahashi, M. B Anand-Srivastava, and S. Takeo Characterization of cardiac myocyte and tissue {beta}-adrenergic signal transduction in rats with heart failure Cardiovasc Res, April 1, 2001; 50(1): 34 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Varagic, D. Susic, and E. D. Frohlich Cardiovasc Pharmacol Therapeut 6(1):57-63, 2001 Low-Dose ACE with Alphaor Beta-Adrenergic Receptor Inhibitors Have Beneficial SHR Cardiovascular Effects Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 57 - 63. [Abstract] [PDF] |
||||
![]() |
E. D Frohlich Review: Promise of prevention and reversal of target organ involvement in hypertension Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S4 - S9. [PDF] |
||||
![]() |
G. J. Perry, T. Mori, C.-C. Wei, X. Y. Xu, Y.-F. Chen, S. Oparil, P. Lucchesi, and L. J. Dell'Italia Genetic Variation in Angiotensin-Converting Enzyme Does Not Prevent Development of Cardiac Hypertrophy or Upregulation of Angiotensin II in Response to Aortocaval Fistula Circulation, February 20, 2001; 103(7): 1012 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T Weber and Yao Sun Recruitable ACE and tissue repair in the infarcted heart Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 295 - 303. [PDF] |
||||
![]() |
V. V Petrov, R. H Fagard, and P. J Lijnen Transforming growth factor-{beta}1 induces angiotensin-converting enzyme synthesis in rat cardiac fibroblasts during their differentiation to myofibroblasts Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 342 - 352. [Abstract] [PDF] |
||||
![]() |
G. Pons-Llado, M. Ballester, X. Borras, F. Carreras, I. Carrio, J. Lopez-Contreras, A. Roca-Cusachs, J. Marrugat, and J. Narula Myocardial cell damage in human hypertension J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2198 - 2203. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hao, B. Wang, S. C. Jones, D. S. Jassal, and I. M. C. Dixon Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H3020 - H3030. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sakata, T. Masuyama, K. Yamamoto, N. Nishikawa, H. Yamamoto, H. Kondo, K. Ono, K. Otsu, T. Kuzuya, T. Miwa, et al. Calcineurin Inhibitor Attenuates Left Ventricular Hypertrophy, Leading to Prevention of Heart Failure in Hypertensive Rats Circulation, October 31, 2000; 102(18): 2269 - 2275. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |